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The growth plate is the area of cartilaginous tissue located at ends of long bones that drives 
skeletal growth in children. Damage to the growth plate can cause formation of bony tethers 
bridging the epiphysis and metaphysis, ultimately leading to growth disturbances. Surgical 
procedures are required to correct these deformities, particularly when lower limbs are involved. 
However, they are costly and often ineffective, driving a clear need for a regenerative approach 
for growth plate repair.  
The growth plate consists of populations of chondrocytes at distinct stages of 
differentiation. The coordinated proliferation and differentiation of the chondrocytes drive bone 
growth. Prior studies have attempted to restore the growth plate using tissue engineering methods. 
Nevertheless, no approach has succeeded in preventing bony tethers and restoring growth plate 
structure. 
In this dissertation, a composite hydrogel (PGH) was developed and evaluated for growth 
plate repair. It consists of Poly (ethylene glycol) diacrylate, methacrylated Gelatin (GEL-MA), 
and methacrylated Heparin. The PGH hydrogel was fabricated in-house and characterized for 
physiochemical properties including mechanical stiffness, swelling properties, and 
cytocompatibility. To evaluate the potential of the hydrogel to regenerate the growth plate 
cartilage, its effects on chondrocyte phenotype progression were analyzed and compared to a GEL-
MA only hydrogel. To evaluate its ability to drive differentiation of stem cells to growth plate 
 v 
chondrocytes, its effects on stem cell chondrogenic and osteogenic differentiation were evaluated. 
Finally, the efficacy of the stem cell-laden PGH hydrogel in regenerating cartilage and preventing 
bony tethers was accessed in a growth plate defect model in goats. The results showed that 
compared to the GEL-MA hydrogel, the PGH hydrogel maintained glycosaminoglycan production 
by hypertrophic chondrocytes, arrested terminal differentiation, and inhibited mineralization. 
While supporting chondrogenesis, it did not permit osteogenesis or mineral deposition by stem 
cells. When implanted into a growth plate defect, the PGH hydrogel was biodegradable and 
supported chondrogenesis. Although unable to completely prevent bony tether formation, 
implantation of the PGH hydrogel reduced bone and increased fat content at the defect site. This 
work advanced understanding of the regenerative approach for growth plate repair. The PGH 
hydrogel also showed great potential in regenerating stable cartilage.  
 
 vi 
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1.1 Bone and Growth Plate Formation 
The 206 bones in our bodies allow us to sit, walk, and conduct everyday life. Despite 
coming in different sizes and shapes, all bones are formed using one of the two methods, 
intramembranous or endochondral ossification, and both begin with mesenchymal condensations 
[1, 2].  
The scapula, craniofacial bones, clavicles, and parts of the pelvis form via 
intramembranous ossification, where the mesenchymal condensation directly differentiate into 
osteoblasts, produce matrix rich in type I collagen, and later mineralize and mature. 
Intramembranous ossification also takes place at the periosteum of all bones [1-3].  
The appendicular skeleton, vertebrae, and the base of the skull form by endochondral 
ossification, a sophisticated and highly coordinated process, where the mesenchymal stem cells 
undergo chondrogenesis and form anlagen, a cartilaginous model, abundant in type II collagen 
and glycosaminoglycans. The chondrocytes proliferate and secrete cartilage matrix, resulting in 
enlargement of the anlagen. Maturation of the chondrocytes first appears in the central region of 
the anlagen, characterized by exiting the cell cycle, hypertrophy, and production of type X 
collagen. The hypertrophic chondrocytes secrete molecular signals to attract blood vessels, 
chondroclasts, and osteoclasts from the perichondrium, forming the primary ossification centers. 
These chondrocytes also facilitated the formation of bone collars by inducing the neighboring 
perichondrial cells to become osteoblasts. At the last stage of life, hypertrophic chondrocytes 
undergo apoptosis. Osteoblasts use the cartilage matrix as a scaffold to lay down trabecular bone, 
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followed by the formation of bone marrow. During the establishment of the primary ossification 
centers, the anlagen continue to grow, driven by chondrocyte proliferation. In long bones, a subset 
of chondrocytes assume a flat shape and exhibit anisotropic arrangement; they stack into parallel 
columns, along the direction of longitudinal growth [1-3].  
While the primary ossification centers establish in the late fetal period, the secondary 
ossification centers emerge soon after birth, at one or both epiphyses, through a similar 
mechanism as the former. The discoid cartilaginous region between the primary and secondary 
ossification centers is called the primary growth plate, or physis, responsible for uniaxial 
elongation of the long bones. Like the primary growth plate, the secondary growth plate, also 
known as the acrophysis, is located at the ends of the long bones. It drives the growth of the 
secondary ossification center [1-5]. The growth plate discussed henceforth refers to the primary 
growth plate.  
1.2 Growth Plate Physiology and Bone Growth 
The growth plate is relatively flat during infanthood, and gradually become undulated as 
children grow. The formation of new cartilage on one side and clearance of calcified cartilage on 
the other is intricately balanced. Therefore, the height of the growth plate remains reasonably 
constant until late adolescence when the growth plate narrows and eventually fuses [2, 5].  
The growth plate is highly cellular, with chondrocytes organized into anisotropic, 
columnar structures [5, 6]. Growth plate chondrocytes can be categorized into five distinct zones, 
namely the reserve zone (RZ), the proliferative zone (PZ), the prehypertrophic zone (PHZ), the 
hypertrophic zone (HZ), and the calcified zone (Figure 1-1). The reserve zone, also known as the 
 3 
resting zone, is located at the leading edge of the growth plate, adjoining the epiphyseal trabecular 
bone. The reserve zone cells (Figure 1-2 A) are round and dispersed, residing in a matrix primarily 
made of horizontally aligned type II collagen fibers. They are believed to give rise to chondrocytes 
in the adjacent proliferative zone. Chondrocytes in the proliferative zone (Figure 1-2 B) have high 
mitotic activity, as the name suggests. After mitosis, the daughter cells do not move throughout 
their life. Proliferative chondrocytes are flat and discoid, lie one on top of another, forming 
chondrocyte columns along the direction of bone growth. Cartilage matrix rich in 
glycosaminoglycans and vertically aligned type II collagen is produced in this zone. In young 
children, the average cell cycle time for proliferative chondrocytes is approximately 20 days. 
Under the orchestration of several signaling pathways, proliferative chondrocytes, starting with 
ones at the bottom of the column, exit the cell cycle and enter the prehypertrophic phase. The 
prehypertrophic zone is sometimes deemed as part of the hypertrophic zone. Cells in the 
prehypertrophic zone (Figure 1-2 C) then undergo massive cell volume enlargement, namely 
hypertrophy, hallmarked by the production of type X collagen. Hypertrophic chondrocytes 
(Figure 1-2 D) exhibit high metabolic activity, evident by a significant increase in the mean 
cellular mitochondrial volume, the mean cellular surface area of Golgi membranes, and the rough 
endoplasmic reticulum. Hypertrophic chondrocytes deposit hydroxyapatite into the surrounding 
matrix, through matrix vesicles, resulting in cartilage mineralization. Hypertrophic chondrocytes 
are also responsible for attracting blood vessels from the metaphyseal bone, by secreting vascular 
endothelial growth factor (VEGF). These cells then undergo apoptosis or transdifferentiate into 
osteoblast and osteocytes. Roughly, 70% of the calcified cartilage is resorbed by chondroblasts 
and the remaining 30% functions as a template for new bone formation. This sequential 
differentiation process, beginning with chondrocyte proliferation at the top of the columns and 
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ending with terminal cell removal at the bottom of the columns, repeats and drives growth until 







Figure 1-1 Growth plate cellular architecture (goat). Safranin O, Fast Green, and hematoxylin stain. Pink 





Figure 1-2 Growth plate chondrocytes (goat): A) resting ; B) proliferative; C) prehypertrophic; D) 




Parathyroid hormone-related protein (PTHrP) and Indian hedgehog (IHH) are two 
essential paracrine factors that collaboratively regulate proliferation and differentiation of 
chondrocytes in the growth plate (Figure 1-3). Proliferative chondrocytes and perichondrial cells 




proliferative chondrocytes signal the cells to continue dividing. As chondrocyte columns 
elongate, the PTHrP source moves away from the cells at the bottom. When the distance is far 
enough, these cells become prehypertrophic and begin to produce IHH. IHH secreted by 
prehypertrophic and early hypertrophic chondrocytes then diffuses towards the epiphysis. It binds 
to its receptor Patched-1 (Ptc-1) on proliferative chondrocytes to promote cell division and PTHrp 
production. Besides the PTHrP/IHH feedback loop, other pivotal pathways in endochondral bone 
formation include fibroblast growth factor (FGF), bone morphogenetic proteins (BMPs), insulin-







Figure 1-3 PTHrP and IHH signaling in the growth plate. Adapted from source, used with permission of [2]. 
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On average, children between 5 and 8 years old grow 1-4 cm each year. The proliferative 
zone and the hypertrophic zone are critical to growth (Figure 1-4). The daily growth rate can be 
calculated by multiplying the number of proliferative chondrocytes, their division rate, and the 







Figure 1-4 The height difference between the hypertrophic chondrocyte column and the original reserve 
zone cell is the amount of growth contributed by that progenitor cell.  






1.3 Growth Plate Injury and Bony Tether Formation 
Due to its soft cartilaginous nature, the growth plate is highly susceptible to fractures. 
Growth plate related bone fractures account for 15% to 30% of all pediatric skeletal injuries. Less 
common etiologies of growth plate injury include infection, cancer, radiation, ischemia, and 
iatrogenic damage [12, 15-17].  
The Salter-Harris classification system (Figure 1-5) is the standard system used to 
evaluate growth plate fractures. It was established in 1963 by Robert B. Salter and W. Robert 
Harris. It categorizes all growth plate fractures into five types based on their pattern and severity. 
80% of growth plate fractures are type I and type II, which are not transphyseal and able to heal 
on their own, unlikely to cause growth disturbances. Types III-V injuries involve damaged 
epiphyseal blood supply and sometimes allow transphyeal blood vessel invasion, likely to result 
in bony tethers and subsequent premature growth arrest [9, 12, 18]. Clinically, bony tethers are 
often detected months after injury. They are first identified or suggested by radiographs, then 









Bony tether formation begins with infiltration of inflammatory cells (Figure 1-6 A), 
including neutrophils, macrophages, and lymphocytes, into the fracture site. Expression of 
transforming growth factor β-1 (TGFβ-1) and bone morphogenetic proteins (BMPs) increase 
during this phase. In rats, neutrophil chemokine Cinc1 (equivalent to interleukin 8 in human) is 
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present in the damaged growth plate shortly following the injury, then decreases over time. The 
neutrophil-mediated inflammatory response is believed to regulate gene expressions during 
downstream repair processes. Pro-inflammatory cytokines interleukin 1 beta (Il1b) and tumor 
necrosis factor alpha (TNFα) are up-regulated at the injured site. TNFα has been shown to play 
an essential role in stem cell recruitment, proliferation, and differentiation during bone fracture 
repair. Arasapam et al. have demonstrated that the inhibition of cyclooxygenase 2 enzyme and 
inducible nitric oxide synthase activity decreased chondrogenesis of the recruited mesenchymal 
cells. Likewise, Chung et al. showed that blocking neutrophil activity favored expression of 
osteogenic genes such as Runx2 and osteocalcin, and decreased expression of chondrogenic genes 
such as Sox9 and type II collagen. [9, 19, 20]. Modulating inflammatory responses during growth 
plate fracture repair may have beneficial effects on bony tether prevention. Infiltration of a mixed 
population of mesenchymal cells (Figure 1-6 B) occurs following the inflammatory responses, 
with stem cell-like cells, osteoprogenitor cells, pre-osteoblasts, and pre-chondroblasts. Production 
of platelet-derived growth factor (PDGF) and fibroblast growth factor 2 (FGF2) increases during 
this phase; they are responsible for promoting cell proliferation, migration, and angiogenesis. 
These cells then undergo chondrogenic and osteogenic differentiation, produce bone matrix 
proteins such as type I collagen and osteocalcin, and eventually lay down bony trabeculae. 





Figure 1-6 Bony tether formation. A) Infiltration of inflammatory cells; B) infiltration of mesenchymal cells; 
C) bone formation; D) bone maturation. 
1.4 Treatments for Growth Plate Injuries 
Bony tethers formed following growth plate injuries can cause lifelong disabilities such 
as limb length discrepancy and angulation deformities. These patients may suffer from cosmetic 
deformity, early-onset arthritis, lower back pain, and gait disturbances. Growth disturbances are 
not well tolerated, especially in the lower limbs. The distal femur, distal tibia, and proximal tibia 
are the most common sites affected by bony tethers post trauma, accounting for 81% of the cases. 
Injury to the growth plate in the distal femur is particularly worrisome, as 71% of the uniaxial 
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growth of the femur and 40% of the lower extremity elongation is driven by the distal femur 
growth plate [12, 14, 17, 21]. 
Surgical interventions are often required to prevent or correct severe growth disturbances. 
When bony tethers affect over 50% of the growth plate, epiphysiodesis is recommended. Young 
children with bony tethers comprise less than 50% of the growth plate area are typically treated 
with tether excision [17]. To prevent reformation of bony tethers, surgeons fill the resection sites 
with interpositional materials. This procedure was first proposed by Langenskiöld et al. in 1949 
[22], and confirmed by Österman et al. in 1972 [23]. In the past 60 years, various materials have 
been tested for this procedure, including polymeric silicone, autologous fat, muscle, bone wax, 
and bone cement. Although this procedure is reported effective in rabbits, it only has 18%-35% 
success rate in human patients [22, 24, 25]. These non-regenerative interpositional materials 
either break down over time, being replaced by new bony tethers or fail to integrate with host 
tissues. Other treatments to reconstruct growth plate function include distal limb transfer, 
rotationplasty, wedge osteotomy, and distraction osteogenesis [9, 12]. These surgical treatments 
are costly, both monetarily and psychologically. They may restrict children’s activity during their 
formative years and subjects them to painful procedures, repeated clinic visits, multiple surgeries, 
and rehabilitation.  
1.5 Regenerative Approaches for Growth Plate Repair 
In search of a more effective solution for growth plate repair, biological treatments have 
been explored in the past three decades. An ideal regenerative approach should not only prevent 
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bony tether formation but also restore the growth plate cartilage and facilitate normal growth for 
children with significant defect size [9, 12, 26].  
Prior studies have attempted to regenerate growth plate cartilage using tissue engineering 
methods translated from articular cartilage engineering, including combinations of cells, growth 
factors, and biomaterials. Bruce Foster and colleagues are pioneers of studying cell-based therapy 
for growth plate application. In 1990, they demonstrated that the use of a chondrocyte-laden 
collagen gel successfully prevented bony tether formation in sheep [27]. In 1998, Lee et al., 
implanted chondrocyte-laden agarose gel in rabbits and showed alleviation of leg length 
discrepancy and angulation deformity [28]. Despite the promising results, chondrocyte based 
therapies suffer from shortcomings such as source limitations, donor site morbidity, and lengthy 
harvesting and culturing processes, making them unsuitable to be used clinically [9, 12, 24]. 
Bone marrow-derived mesenchymal stem cells (BMSCs) have gained popularity as an 
alternative cell source, owing to their abundance and superior chondrogenic capability under 
proper conditions. Several studies have reported some degree of success in the rabbit model; 
nevertheless, such therapy has not succeeded in large animals [9, 29, 30].  
Currently, there is no biological therapy available to regenerate the growth plate cartilage 
and prevent bony tether formation. Recapitulating the unique cellular architecture in the growth 
plate may be the key to regenerate functional growth plate cartilage [12]. The field is open to new 
tools and means to regenerate the growth plate and restore healthy growth. In order to successfully 
generate the growth plate cartilage, the interpositional material has to meet five criteria: 1) support 
cartilage formation; 2) prevent bony tether; 3) restore the zonal cell organization; 4) reestablish 
the appropriate signaling; 5) restore normal growth. Recreating the appropriate cellular 
architecture and signaling of the natural growth plate is exceptionally challenging, as it is a highly 
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stratified and dynamic tissue and the signaling mechanisms that orchestrate the proper 
chondrocyte maturation are not fully understood. Therefore, this work focused on developing an 
interpositional material that meets the first two criteria. Four specific aims have been crafted as 
discussed henceforward. 
1.6 Specific Aims 
The goal of this work is to develop a stem cell-laden composite hydrogel as the 
interpositional material for growth plate repair. This hydrogel should support cartilage 
development while preventing bone formation. We choose to develop a photocrosslinkable 
composite hydrogel consisting of poly (ethylene glycol) (PEG) diacrylate (PEGDA), 
methacrylated gelatin (GEL-MA), and methacrylated heparin (HEP-MA). The rationale of 
polymer selection is elucidated in section 2.1.  
 
The specific hypothesis to be tested by the specific aims below is that the PEGDA-(GEL-
MA)-(HEP-MA) composite hydrogel (PGH) will: 
1) Support cartilaginous matrix deposition by proliferative chondrocytes but inhibit 
terminal differentiation and mineralization by chondrocytes, 
2) Support stem cell chondrogenesis while inhibiting osteogenesis, and 
3) Regenerate growth plate cartilage while preventing bony tether formation. 
 
A summary of the specific aims of this dissertation to achieve the work described above 
are given below: 
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Specific Aim 1: Fabricate and characterize the PGH hydrogel. 
In this specific aim, the PGH hydrogel was fabricated using PEGDA, GEL-MA, and HEP-
MA synthesized in-house. Modification of the polymers was confirmed and calculated by proton 
nuclear magnetic resonance (1H NMR). Material properties of the hydrogel were evaluated by 
mechanical testing and swelling assay. Cytocompatibility was assessed by Live/Dead assay.  
 
Specific Aim 2: Evaluate the effects of the PGH hydrogel on chondrocyte phenotypes in a 
murine subcutaneous implant model.  
This experiment modeled response of growth plate chondrocytes to the PGH hydrogel. 
Tri-layered PGH hydrogels encapsulating growth plate-like chondrocytes obtained from 
embryonic chick sternum were implanted into mouse dorsal subcutaneous pockets for 1, 3, and 8 
weeks. Production of GAGs, types I, II, and X collagen, alkaline phosphatase activity, mineral 
deposition, and apoptosis were analyzed.  
 
Specific Aim 3: Evaluate the effects of the PGH hydrogel on stem cell chondrogenesis and 
osteogenesis in vitro and in vivo.   
In this specific aim, stem cell-laden PGH hydrogels were subject to chondrogenic and 
osteogenic medium in vitro. Production of GAGs and minerals were analyzed. Also, the stem 
cell-laden PGH hydrogels were implanted into mouse dorsal subcutaneous pockets for 8 weeks. 




Specific Aim 4: Assess the efficacy of the stem cell-laden PGH hydrogel in cartilage 
regeneration and bony tether prevention in a growth plate injury model in goats. 
Ultimately, stem cell-laden PGH hydrogels were implanted into growth plate defects in 
3-month-old goats. Bony tether formation, tissue composition within the injured site, and the fate 
of the hydrogels and encapsulated stem cells were analyzed and discussed.  
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2.0 Specific Aim 1: Fabricate and Characterize the PGH Hydrogel 
2.1 Introduction 
Hydrogels have been widely used for cartilage regeneration since the 1990s. The three-
dimensional (3D) hydrophilic characteristic of hydrogels provide a microenvironment resembling 
the native cartilage extracellular matrix (ECM), supporting encapsulated cells to adhere, 
proliferate, and differentiate. Also, their porous framework enables cell migration as well as 
diffusion of growth factors, nutrients, and metabolites [31].  
Among a variety of biomaterials, we chose to develop a photocrosslinkable composite 
hydrogel consisting of poly (ethylene glycol) (PEG) diacrylate (PEGDA), methacrylated gelatin 
(GEL-MA), and methacrylated heparin (HEP-MA).  
We have focused on photopolymerizable hydrogels because they can be used to 
encapsulate different cell types and to incorporate numerous growth factors to guide the 
regeneration of cartilaginous interfacial tissues [32-34]. Also, the photocrosslinkable nature 
allows the hydrogels to be used as a potential injectable material to match irregular defects in the 
growth plate [31]. 
The PEG component was incorporated as a bioinert base to maintain spherical cell shape 
and resist cell-mediated contraction [35, 36]. Gelatin is a highly biocompatible and biodegradable 
natural polymer obtained by partially hydrolyzing collagen [31]. It offers integrin-mediated 
adhesion sites crucial for chondrocyte survival, proliferation, column formation, and hypertrophy 
[37-40]. The addition of heparin, the most negatively charged glycosaminoglycan (GAG), further 
mimics the matrix composition of cartilage and prolongs retention of growth factors produced by 
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encapsulated chondrocytes [41-47]. Heparin is selected as an analog to heparan sulfate (HS) 
proteoglycans, which are critical for normal intercellular signaling in the growth plate. Severe 
deficiency of HS in the growth plate leads to multiple osteochondromas [48, 49]. Also, heparin 
and other sulfated GAG-containing proteins have been shown to inhibit the formation of 
amorphous calcium phosphate, aggregation, and growth of crystalline apatite [50-53], and 
mineralization by osteoblasts in vitro [54-56].  
In this aim, the PGH hydrogel was fabricated in-house and characterized for 
physiochemical properties including mechanical stiffness, swelling properties, and 
cytocompatibility. These properties were compared to the commonly employed GEL-MA only 
hydrogel (GEL). Chondrocytes are mechanosensitive, and their phenotype can be altered by 
substrate stiffness and mechanical stress [57, 58]. Swelling property of the hydrogels affects the 
mechanical properties, growth factor and metabolite diffusion, and surface properties [59].   
 
 
2.2 Materials and Methods 
2.2.1  Materials 
Poly (ethylene glycol) (PEG) (MW ~4000), type B gelatin from bovine skin 
(MW~45000), dichloromethane, triethylamine, diethyl ether, methacrylic anhydride, molecular 
sieves (4Ǻ), and dialysis tubing were obtained from Sigma-Aldrich (St. Louis, MO). Heparin 
sodium salt (MW = 15000) and other chemicals for material synthesis were obtained from Thermo 
Fisher Scientific (Hampton, NH). Cell culture supplies were purchased from Atlanta Biologicals 
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(Flowery Branch, GA) and Thermo Fisher Scientific (Waltham, MA). Live/Dead® 
Viability/Cytotoxicity kit was purchased from Invitrogen (Carlsbad, CA). Human BMSCs 
(hBMSC) and expansion medium were purchased from RoosterBio, Inc (Frederick, MD). 
Deuterium oxide was purchased from Sigma-Aldrich.  
2.2.2  Synthesis of PEGDA, GEL-MA, HEP-MA, and Photoinitiator 
PEGDA was synthesized as described previously [60]. Briefly, 33% (w/v) PEG solution 
in dichloromethane was prepared and reacted with methacrylated anhydride and triethylamine for 
four days in the dark at room temperature. The reaction mixture was then precipitated in diethyl 
ether, dialyzed against five changes of distilled water over 12 hours, frozen and lyophilized. GEL-
MA was synthesized as described previously [59, 61]. Briefly, a 10% (w/v) gelatin solution in 
phosphate buffered saline (PBS, pH 7.2) was prepared and reacted with methacrylated anhydride 
under stirring at 50°C on a hot plate for 1 hour. The reaction mixture was then neutralized to pH 
7.4, dialyzed against five changes of PBS over 48 hours, and lyophilized. HEP-MA was 
synthesized as described previously [62]. Briefly, a 10% (w/v) heparin solution in distilled water 
was prepared and reacted overnight with methacrylic anhydride at pH 8.5, 4°C. The reaction 
mixture was then precipitated in ethanol, dialyzed against five changes of distilled water over 48 
hours, and lyophilized. The photoinitiator lithium phenyl-2,4,6-trimethylbenzoyl phosphinate 
(LAP) was synthesized in-house via the method of Majima et al. 1991 [63]. Briefly, 4,6-
trimethylbenzoyl chloride was added dropwise to dimethyl phenylphosphonite and stirred over 
18 hours. An excess of lithium bromide in 2-butanone was added and heated to 50°C for 10 
minutes. The product was filtered, washed with 2-butanone, and dried.  
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2.2.3  NMR Analysis 
Degrees of modification of the polymers were determined using 1H NMR. Briefly, 30 mg 
of modified or unmodified polymers were dissolved in 0.6 mL deuterium oxide (D2O). 1H spectra 
were measured at 300 MHz (Advance III, Bruker, Germany), phase corrected and integrated. 
Three characteristic signals corresponding to the vinyl double bond were observed at 1.8, 5.7, and 
6.2 ppm. The degree of modification (DOM) of PEGDA was calculated as described previously 
[64]. Briefly, the integration of vinyl protons at 5.8-6.2 ppm was compared to the integration of 
the two methylene bridge protons (-CH2-) at the terminal ends at 4.3 ppm. DOM=average integral 
of allylic proton/average integral of terminal methylene bridge proton. The degree of modification 
of GEL-MA was calculated as described previously [65]. Briefly, the integral ratio of lysine 
residues at 2.9 ppm (2.8 – 2.95) after modification to pre-modification was calculated (signal is 
lost with modification). DOM = 1- (integral of lysine signal of GEL-MA/ integral of lysine signal 
of unmodified gelatin). The degree of modification of HEP-MA was calculated as described 
previously [66]. Briefly, integration of the two methacrylate vinyl protons at 5.7 and 6.1 ppm 
were compared to the integration of the protons on the disaccharide unit of heparin at 3.0-4.6 
ppm. DOME=average integral of the vinyl protons/average integral of the protons on the 
disaccharide unit.  
2.2.4  Hydrogel fabrication 
The hydrogel solutions were prepared by dissolving the modified polymers at 10% (w/v) 
in PBS. The PEG-DA solution was degassed before use. The photoinitiator LAP was added to 
hydrogel solutions at a final concentration of 0.01% (w/v). The PGH hydrogel was composed of 
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PEGDA, GEL-MA, and HEP-MA at a 63:21:16 mass ratio. The GEL hydrogel was 10% (w/v) 
GEL-MA only. For the cytocompatibility assay, cells were added to the hydrogel solutions at 1 
million/mL. The hydrogel solutions were poured to a height of 2.0 mm into a 
polydimethylsiloxane mold with a glass bottom and polymerized with 2.5 J/cm2/mm UV-A (365 
nm filter) from an Omnicure S1000 light source (InPro Technologies, Frederick, MD) for 3.5 
minutes. Cylindrical hydrogel constructs were cut using biopsy punches.  
 
2.2.5  Mechanical Testing 
Cylindrical hydrogels were made using an 8.0 mm biopsy punch. The unconfined 
compression properties of the hydrogels were determined using an Insight 1 electromechanical 
testing system with a 10 N load cell (MTS Systems, Eden Prairie, MN) and PBS bath at room 
temperature (n=3 per hydrogel type). Samples were equilibrated for 1 hour in PBS before testing. 
Immediately before testing, cylinder diameter and height were measured with calipers, and then 
cylinders placed between aluminum platens and preloaded to 0.02 N at 0.008 mm/s. After 30 
minutes of relaxation, cylinder height was recorded, and then cylinders were pre-conditioned with 
10 cycles of 10% strain at 0.0015 strain/s. Force versus displacement data was then recorded for 
a 10% strain ramp (0.0015 strain/s) followed by 30 minutes stress relaxation using TestWorks 
(v4.11C, MTS Systems.) Engineering stress and strain were used to determine dynamic modulus 
(using the tangent to the linear region of the force/displacement curve at the last 1% of applied 
strain) and relaxation modulus for isotropic viscoelastic solids.  
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2.2.6  Swelling analysis  
Cylindrical hydrogels were made using a 5.0 mm biopsy punch. Each cylinder was 
immersed in 2 ml of PBS and incubated at 37°C with PBS exchanged every week. Samples were 
retrieved at the indicated time-points (Figure 2-3, n=3 per time-point), blotted, weighed (Ws = 
wet weight), dried, and weighed (Wd = dry weight). The swelling ratio (Q) was calculated as 
follows: Q= (Ws-Wd)/Wd. 
 
2.2.7  Cytocompatibility 
Human BMSCs were expanded for three passages (1 week each) for experimental use. 
Cells were cultured until 80% confluence, trypsinized, and plated at 7.5×105 cells per 175 cm2 
cell culture flasks.  5 mm diameter cell-laden cylinders were fabricated as described in section 
2.2.4. They were incubated in culture medium (alpha minimum essential medium (α-MEM), 1% 
penicillin/streptomycin (P/S), 10% fetal bovine serum (FBS)) for one day post-crosslinking and 
stained with the Live/Dead® Viability/Cytotoxicity Kit following the manufacturer's protocol. 
The percentage of live cells was calculated based on the number of green stained cells divided by 
the total number of cells (green and red stained cells, dual stained counted once as dead). 
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2.3 Results 
2.3.1  NMR Analysis 
The NMR spectra (Figure 2-1) showed that PEGDA was 92.5% modified; GEL-MA was 
100% methacrylated due to the absence of the amine signals at 2.8–2.95 ppm; the degree of 
modification for HEP-MA was 10.4% (10.4 methacrylate groups/100 disaccharide units). There 










2.3.2  Physical Properties and Cytocompatibility 
The PGH hydrogel showed a significantly lower relaxation modulus (9.5 kPa, p=0.01) 
and peak stress (1.9 kPa, p=0.038) at 10% strain in unconfined compression compared to GEL 
(17.2 kPa and 2.4 kPa respectively, Figure 2-2). The dynamic modulus was not significantly 







Figure 2-2 Unconfined compression moduli and peak stress at 10% strain for GEL and PGH (both 10% 
w/v) at room temperature in PBS bath (* = p < 0.05). 
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The PGH hydrogel likewise showed significantly greater swelling than the GEL hydrogel 
immediately after immersion in PBS (within 2 hours, Figure 2-3). Both hydrogel types swelled 
immediately after two hours and appeared stable over the six-week assay. The GEL hydrogel 
seemed to shrink somewhat in the first weeks. We attribute this possible shrinkage to the syneresis 
of the scaffold. Both hydrogels were slightly off the designed 10% (w/v) density. Both hydrogels 













Figure 2-4 Live/Dead staining of BMSCs embedded in the PGH and GEL hydrogels one day post-
crosslinking in expansion medium. (A) The fraction of viable cells in GEL hydrogels. (B) The fraction in 
PGH hydrogels. 
2.4 Discussion 
Regarding the physical and cytocompatibility properties of the hydrogels, the significantly 
weaker in relaxation modulus of PGH hydrogels compared to GEL hydrogels suggests a lower 
crosslink density in PGH. The comparable dynamic modulus suggests similar permeability 
between the hydrogels. The low density of the fixed-charge sulfate groups in PGH likely does not 
add significant electrostatic repulsion to the relaxation modulus or streaming potential in the flow-
dependent viscoelastic behavior. Thus, these contributing factors would result in a lower 
relaxation modulus. The significantly greater swelling of the PGH hydrogel immediately on 
immersion likely arises from the lower crosslink density and increased Donnan osmotic pressure 
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due to the heparin sulfate groups. The variation in the starting density of both hydrogels arose 
from the error in weighing the low masses of polymer precursors for small-batch manufacturing. 
In the future, the degradation property of the PGH hydrogel should also be investigated. The 
gelatin and heparin components of the PGH hydrogel are expected to degrade first through 
enzymatic mechanisms, while the PEG component is expected to degrade slowly via oxidation of 
the ether backbone and hydrolysis of the esters. As components of the hydrogel degrade, the 
polymer network weakens and eventually falls apart. The PGH hydrogels studied in this 
dissertation were composed of PEG, gelatin, and heparin at 63:21:16 mass ratio. This design 
enabled the hydrogel constructs to remain for a longer time so that we could retrieve the samples 
for analysis at the end of the experiments. The cytocompatibility assays were performed after one 
day post-crosslinking to capture potential necrosis which may occur over time due to the hydrogel 
components and irradiation, as opposed to that from merely handling the cells for encapsulation 
(e.g., trypsinization, pipetting, mixing). The 86% viability is similar to other hydrogels [67, 68]. 
LAP and GEL-MA have been used by Allevi, a 3D bioprinting company, for tissue engineering. 
Allevi has demonstrated that when combining with photocrosslinkable polymers, the activated 
photoinitiator did not affect cell viability, whereas unreacted photoinitiators could pose harm on 
cells. It is important to note that in our experiment, no methods were used to augment viability 
under radical initiated crosslinking (e.g., ascorbate pretreatment of cells). 
2.5 Conclusion 
The PGH hydrogel was successfully fabricated with comparable cytocompatibility as 
other hydrogels for tissue engineering. Characterization of the physical properties of the hydrogel 
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allows us to optimize the PGH hydrogel for cartilage regeneration and bony tether prevention in 
the future.  
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3.0 Specific Aim 2: Evaluate the Effects of the PGH hydrogel on Chondrocyte Phenotypes 
in a Murine Subcutaneous Implant Model 
3.1 Introduction 
The growth plate (physis), consists of spatially discrete but proximate populations of 
chondrocytes at distinct states of differentiation. The populations can be grouped into five zones 
in the growth plate: 1) reserve zone (RZ), a reservoir of round dispersed progenitor cells; 2) 
proliferative zone (PZ), stacks of disk-like proliferating chondrocytes originated from progenitor 
mitosis and “gliding” reorganization; 3) prehypertrophic zone (PHZ), an interface where stacking 
cells leave the proliferative state and commit to terminal differentiation; 4) hypertrophic zone 
(HZ), where chondrocytes undergo terminal differentiation accompanied by massive cell 
enlargement; and 5) calcified zone (CZ), an interface of trabecular bone and the growth plate 
cartilage, where chondrocytes deposit minerals and eventually undergo apoptosis [8, 69-72]. 
Bioactive factors released by growth plate chondrocytes and the surrounding perichondrium 
interact with cells in both neighboring and distant zones and orchestrate chondrocyte maturation 
[2]. The coordinated progression of chondrocytes through all states of differentiation drives 
endochondral ossification and limb growth. Growth begins with immature resting RZ cells exiting 
from a metabolically quiescent state and entering a column forming phase as PZ cells. Next, they 
leave the cell cycle and increase secretion of cartilage matrix molecules such as type II collagen 
(Col2) and proteoglycans containing glycosaminoglycans (GAGs) as PHZ. Then they undergo 
hypertrophy hallmarked by type X collagen (Col10) production and a 10-fold increase in cell 
volume as HZ cells. HZ chondrocytes facilitate mineralization of the cartilage matrix by 
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depositing hydroxyapatite via matrix vesicles, and are eventually are removed by apoptosis or 
transdifferentiate into osteoblast and osteocytes [8, 11, 73-76].  
To fully repair the growth plate cartilage and restore growth, it may be necessary to re-
establish the zonal organization [12]. However, no study has been able to regenerate the natural 
cellular architecture of the growth plate. Transplantation of the intact physis has been pioneered 
for severe pathology but is extremely invasive and high risk rendering it unsuitable for most needs 
[77, 78]. Thus, the field is open to new tools and means to regenerate the growth plate and restore 
normal growth.  
  Control over chondrogenesis and chondrocyte phenotype progression is needed to inhibit 
boney tether formation in injured growth plates, and to ultimately regenerate the cellular 
architecture of growth plate.  
To better understand the potential of the hydrogel to recreate the growth plate structure, 
we evaluated the effect of GEL (GEL-MA only) and PGH on the progression of growth plate-
like chondrocytes through their states of differentiation. We hypothesized that the PGH would 
support enhanced matrix deposition by proliferative chondrocytes but inhibit terminal 
differentiation and mineralization by chondrocytes, whereas the GEL would support normal 
chondrocyte maturation and mineral deposition. We utilized a layered-photocrosslinking 
technique to fabricate tri-layered hydrogel constructs that mimicked the growth plate zonal 
architecture. Namely, we isolated PZ, PHZ, and HZ chondrocytes from discrete regions of day 
17 chick sterna and encapsulated them in discrete layers within a monolithic hydrogel construct. 
The chick sternum is composed of chondrocytes of similar phenotype to growth plate 
chondrocytes. The caudal region of the sternum contains immature PZ-like chondrocytes, 
producing collagen type II, IX, XI, and PTHrp. The middle region contains PHZ-like 
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chondrocytes, producing Indian hedgehog (IHH). The cephalic (cranial) region contains HZ-like 
chondrocytes, producing Col10, alkaline phosphatase (ALP) and driving mineralization [74, 79-
81]. The chick sterna were harvested and repeatedly dissected into consistent regions from which 
a large number of cells required for this study were pooled. The hydrogels were implanted in 
subcutaneous pockets of immunocompromised mice and allowed to mature over eight weeks of 
growth. Subsequently, the constructs were harvested, and chondrocyte phenotype and matrix 
composition analyzed via histochemical and immunohistochemical analysis.  
3.2 Materials and Methods 
3.2.1  Materials 
PEGDA, GEL-MA, HEP-MA, and LAP were synthesized in-house as described in section 
2.2.2. Collagenase (#C1764 from Clostridium histolyticum), dimethyl sulfoxide (DMSO), 
sucrose, ALP activity stain (BCIP®/NBT Liquid Substrate System), and Alizarin red were 
purchased from Sigma-Aldrich (St. Louis, MO). O.C.T. Compound was purchased from Thermo 
Fisher Scientific (Hampton, NH). Cell culture supplies including alpha minimum essential 
medium (α-MEM), penicillin/streptomycin, phosphate buffered saline (PBS, pH 7.2), and plastic 
ware were purchased from Thermo Fisher Scientific. Fetal bovine serum was purchased from 
Atlantic biologicals (Frederick, MD). The Von Kossa Stain Kit was purchased from American 
MasterTech (Lodi, CA). Antibodies were purchased from Abcam (Cambridge, United Kingdom). 
The TUNEL stain kit (ApopTag®) was purchased from Millipore (Burlington, MA).  
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3.2.2  Chondrocyte Isolation and Culture 
White Leghorn chicken eggs were purchased from Eichner's Farm (Wexford, PA) and 
incubated at 39°C. At embryonic day 17, sterna were removed from hundreds of embryos and 
freed of connective tissues and perichondrial membrane using careful dissection. Separate regions 
of the sterna containing immature proliferative (PZ), prehypertrophic (PHZ), and hypertrophic 
(HZ) chondrocytes were cut as depicted in Figure 3-1, based on our immunohistochemical 
characterization of cell phenotype and the published sternum anatomy [74, 80], and pooled by 
region. The separate pools were incubated in tissue digestion medium (α-MEM, 10% fetal bovine 
serum, 1% penicillin-streptomycin, 20% collagenase) overnight at 37 °C. The chondrocytes were 
isolated by centrifugation and plated in fresh tissue culture medium (α-MEM, 10% fetal bovine 
serum, 1% penicillin-streptomycin) overnight to recover. Subsequently, all chondrocytes were 
released with trypsin treatment and frozen in freeze back medium (10% DMSO and 90% FBS) 
for future use. Before embedding within hydrogels, the chondrocytes were thawed, plated in the 





Figure 3-1 (Left) Cell cource for chondrocyte PZ, PHZ, and HZ populations from sternum after egg 
incubation for 17 days. Immunostain with red = Col2; green = Col10; surrounding muscle autofluoresces 
green. (Right) Design of cylindrical constructs for subcutaneous growth experiments in mice. 
 
3.2.3  Hydrogel Construct Fabrication 
The tri-layered hydrogel constructs that mimicked the growth plate zonal architecture 
were fabricated by sequentially casting 1.0 mm thick hydrogel layers containing the HZ, PHZ, 
and PZ chondrocytes in that order (Figure 3-1). Constructs were made of entirely PGH or GEL 
using a similar casting procedure as described in Aim 1. Separate solutions of the hydrogel 
precursor were mixed with cells of each population type at 30 million/mL. The first layer was 
Supplemental figure 2. (Left) Cell source for chondrocyte PZ, PHZ, and HZ populations
from sternums after chick incubation for 17 days. Immunostain with red = Col2; green =
Col10; surrounding muscle autofluoresces green. (Right) Design of cylindrical constructs































cast and irradiated, and the next layer immediately cast and irradiated. Bonding between layers 
was assured by casting in ambient air, which inhibits polymerization at the near surface, thus 
ensuring crosslinking between layers. Molecular oxygen quenches the radicals involved in 
crosslinking. The final layer was polymerized under nitrogen gas to crosslink the top surface 
entirely. Cylindrical constructs of 3 mm height x 5 mm diameter were cut out using a biopsy 
punch. The constructs were made the day of surgical implantation and placed in tissue culture 
medium before implantation in the mice.  
 
3.2.4  Murine Subcutaneous Model 
The hydrogel constructs (n=3 minimum per hydrogel) were implanted into separate dorsal 
subcutaneous pockets of immunodeficient mice (5-week old males) under an IACUC approved 
protocol (#15025263) at the University of Pittsburgh. The hydrogel constructs were implanted 
face up or down, randomly. The mice, NOD.CB17-Prkdcscid/SzJ, were purchased from Jackson 
Laboratory (Bar Harbor, ME). The animals were euthanized at 1, 3, and 8 weeks, and constructs 
were collected for analysis. The constructs were immersed in 30% (w/v) sucrose in PBS 
overnight, and then in 40% (v/v) O.C.T. Compound in PBS for two days. They were then snap 
frozen, embedded in O.C.T., and cryosectioned at 10 µm. The implants were analyzed with 
histochemical and immunohistochemical staining for GAGs (Safranin O / Fast Green/ 
Hematoxylin), collagen types I (Col1, Sigma-Aldrich AB752P), II (Col2, abcam ab34712), and 
X (Col10, Thermo Fisher Scientific MA5-14268), mineral (Von Kossa and Alizarin Red), ALP 
activity, and apoptosis (TUNEL method). Images were captured using a Nikon Eclipse TiE 
epifluorescent microscope (Nikon Instruments Inc., Melville NY) fitted with an ORCA-Flash4.0 
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camera (high sensitivity CMOS, Hamamatsu, Middlesex NJ) and NIS-Elements AR v4 software 
(Laboratory Imaging s.r.o., Praha, Czech Republic). The area and intensity of the positive signal 
for each histochemical and antibody stain were quantified using NIS-Element AR. The area of 
matrix deposition per layer was calculated as
𝑆𝑡𝑎𝑖𝑛𝑒𝑑 𝑎𝑟𝑒𝑎
𝑇𝑜𝑡𝑎𝑙 𝑆𝑐𝑎𝑓𝑓𝑜𝑙𝑑 𝑙𝑎𝑦𝑒𝑟 𝑎𝑟𝑒𝑎
. The average content of the 
matrix deposited was calculated as
𝑆𝑢𝑚 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑡𝑎𝑖𝑛 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑣𝑒𝑟 𝑡ℎ𝑒 𝑙𝑎𝑦𝑒𝑟
𝑇𝑜𝑡𝑎𝑙 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑 𝑙𝑎𝑦𝑒𝑟 𝑎𝑟𝑒𝑎
. The concentration of 
matrix deposition was calculated as
𝑆𝑢𝑚 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑡𝑎𝑖𝑛 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
𝑆𝑡𝑎𝑖𝑛𝑒𝑑 𝑎𝑟𝑒𝑎
. These measures of average content 
and concentration were normalized to the group HZ in GEL at one week. The total number of 
cells per layer and those positive for GAG, Col1, Col2, and Col10 were counted, and the fraction 
calculated. 
3.2.5  Statistical Methods 
Statistical analysis was performed on histology measures using two-way ANOVA 
(hydrogel type and time within a chondrocyte population type) with Tukey’s HSD post-hoc tests. 
Data are presented as mean ± standard deviation. 
3.3 Results 
3.3.1  Model Characterization  
At the time of cell harvest (17 days of egg incubation), the long narrow caudal and medial 
regions of the chick sternum from which PZ were isolated stained lower for GAG than the 
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cephalic region from which PHZ and HZ cells were isolated (Figure 3-2 A ). The PZ region 
showed no mineral staining, while the PHZ and HZ regions showed ALP activity but only a few 
sparse nodules of focal mineralization (Figure 3-2 B and 3-1 C). Only the HZ region expressed 
Col10; the PHZ did not (Figure 3-2 D). The upper cephalic region did stain stronger for GAGs 
but was excluded from the HZ due to lack of Col10 expression and interfacing with fibrous tissue. 
Col1 and Col2 were expressed in all three zones (Figure 3-2 D and Figure 3-2 E), with Col1 





Figure 3-2 Day 17 chick sternum. A) Safranin O (red and pink) = GAG, Fast Green (green) = fibrous tissue, 
hematoxylin stain (purple) = cell nuclei. B) Alizarin Red stain (red) = calcium deposition. C) BCIP stain 
(dark purple) = ALP activity, counterstained with Fast Green. D) Immunostain with red = Col2; green = 
Col10; DAPI (blue) = nuclei, surrounding muscle autofluoresces green. E) Immunostain with red = Col1; 




3.3.2  Chondrogenesis  
GAGs and Col2 are among the most abundant ECM components of growth plate cartilage 
[76, 82]. The heparin component of PGH also stained positive for GAGs with Safranin O; this 
background was taken into account during image analysis. Overall, PGH showed greater GAG 
accumulation by all three chondrocyte populations compared to GEL (Figure 3-3 A-F). The area 
of GAG deposition for all three chondrocyte populations significantly increased over time 
(p<0.0001, Error! Reference source not found. A), with the HZ layer showing the lowest 
increase of 68%. However in GEL, only the PZ layer showed a significant increase in GAG 
deposition over the 8 weeks of growth (7.0-fold, p<0.0001). The PHZ layer in GEL showed a 1.2-
fold increase at week 3 (p=0.0057), but then a 42% decrease from week 3 to week 8 (p=0.0304). 
The HZ layer in GEL showed no significant accumulation of GAGs over time. Comparing 
between hydrogel types, all chondrocyte populations showed a significantly greater area of GAG 
deposition in PGH than in GEL at week 8 (p<0.0001), with 11% for PZ, 2.2-fold for PHZ, and 
7.4-fold for HZ. At earlier time-points, PHZ cells did not show differences between hydrogel 
types. The area of GAG deposition for PZ and HZ layers were significantly greater in PGH than 
GEL at week 1 by 2.2- and 12-fold respectively (p<0.0001). At week 3, only the HZ layer showed 
a greater area of GAG deposition in PGH than GEL by 4.3-fold (p<0.0001). The fraction of HZ 
cells that were positive for GAG deposition was at least twofold greater in PGH than in GEL at 
all time-points (p<0.0001, Error! Reference source not found. B). However in PGH, the 
fraction of HZ cells positive for GAG did show a 20% decrease over time (p=0.0225); no 





Figure 3-3 GAG deposition in GEL (A-C) and PGH (D-F) hydrogels by the different chondrocyte 
populations at 1, 3, and 8 weeks of growth in vivo within dorsal subcutaneous pockets in 
immunocompromised mice. Safranin O (red and pink) = GAG, Fast Green (green) = fibrous tissue, 





Figure 3-4 Area of GAG deposition (A) and fraction of GAG positive cells (B) were quantified by image 
analysis. *’’’ = p < 0.0001; *’’ = p ≤ 0.001; *’ = p ≤ 0.01; * = p < 0.05. Error bars = standard 
deviation of the mean. 
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In contrast, GEL showed greater Col2 accumulation by all cell populations compared to 
PGH (Figure 3-5). The average Col2 content in the PZ layer significantly increased over time in 
GEL by 2.2-fold (p<0.0001, Figure 3-6Figure 3-6 A), while the PHZ layer showed no significant 
change over time. In the HZ layer in GEL, Col2 content first decreased at week 3 by 48% 
(p=0.0113), and then increased by 1.0-fold at week 8 (p=0.0173). In the PGH hydrogel, the PZ 
layer showed a significant increase in Col2 content at week 3 (1.2-fold, p=0.0133). The PHZ and 
HZ populations in PGH did not show significant changes in Col2 content over time. Compared 
between hydrogel types, the average Col2 content was significantly greater in GEL than in PGH 
at week 8 for all chondrocyte populations, with threefold for PZ, 2.4-fold for PHZ, and 1.7-fold 
for HZ layers (p≤0.0023). The PHZ and HZ layers in GEL were significantly greater in Col2 
content at week 1 by 1.5-fold and 1.0-fold respectively (p≤0.0076). No significant differences 
were detected between PGH and GEL at week 3.  
The Col2 deposition became distributed throughout the GEL constructs over time, 
beginning in the PZ layer at week 3 and then evident in the PHZ and HZ layers at week 8 (Figure 
3-5). Deposition remained more pericellular in PGH than in GEL (Figure 3-7). The concentration 
of Col2 deposition was significantly greater in PGH than GEL for all cell populations at week 1 
and 3 (p≤0.002, Figure 3-6 B), consistent with a greater diffusion of Col2 away from cells in 
GEL. By week 8, the concentration of Col2 was impacted by the hydrogel type. The PZ layer in 
GEL showed a greater concentration of Col2 than in PGH (13%, p=0.0186), consistent with the 
observed increase in average Col2 content. The PHZ layer in PGH maintained a greater 
concentration of Col2 than GEL (27%, p<0.0001). No significant difference was found between 
hydrogel types for HZ layer at week 8. Changes over time in the concentration of Col2 were 
smaller than changes in the average content of Col2. All layers in PGH showed a significant 
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decrease in the concentration of Col2 over time (p<0.0001 for PZ and PHZ, p=0.0002 for HZ 
from week 1 to week 8). Though the average Col2 content of the PZ layer in PGH increased at 
week 3 (p=0.013), the Col2 concentration decreased (p<0.0001), likely due to farther diffusion of 
the molecule. From week 3 to week 8, there was no significant change in Col2 concentration for 
the PZ and PHZ layers in PGH, while the HZ layer decreased by 22% (p=0.0215).  In GEL 
hydrogels, only the PZ layer showed a significant increase in the concentration of Col2 deposition 
by week 8 (34%, p<0.0001). No significant changes over time were observed in GEL for the PHZ 
and HZ layers. The fraction of cells positive for Col2 significantly decreased in PGH across all 
populations from week 3 to week 8 of growth, by 45% for the PZ, 30% for PHZ, and 25% for HZ 
layers (p≤0.0006, Figure 3-6 C). At week 8, the fraction was significantly greater in GEL than 
PGH by 86% for PZ, 49% for PHZ, and 40% for HZ layers (p<0.0001). No significant differences 
between hydrogels were detected at earlier time-points. In GEL, only the HZ layer showed a 
significant increase in the fraction of Col2 positive cells over time (p<0.0001). No alignment of 





Figure 3-5 Col2 deposition by the different chondrocyte populations over 1, 3, and 8 weeks of growth in vivo 






Figure 3-6 Analysis of Col2 deposition in GEL and PGH hydrogel constructs by the different chondrocyte 
populations over 1, 3, and 8 weeks of growth in vivo. Average Col2 content (A), concentration of Col2 
deposition (B), and fraction of Col2 positive cells (C) were quantified by image analysis. *’’’ = p < 0.0001; *’’ 
= p ≤ 0.001; *’ = p ≤ 0.01; * = p < 0.05. Error bars = standard deviation of the mean.   
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Figure 3-7 Distribution of Col 2 deposition by PZ chondrocytes at 8 weeks of growth. Col2 (red) appeared 
more localized to the pericellular matrix in PGH than in GEL hydrogels.   
3.3.3  Hypertrophy 
Chondrocyte hypertrophy can be characterized by cellular enlargement and expression of 
Col10 and ALP [83-85]. In the hypertrophic zone, Col10 makes up close to half of the total 
collagen [86]. Overall, PGH showed delayed and reduced accumulation of Col10 by PHZ 
chondrocytes. No significant Col10 production by PZ cells occurred at any time-points regardless 
of hydrogel type (Figure 3-8). In GEL, the average Col10 content in PHZ and HZ layers increased 
significantly at week 3, by 5.4- and 7.2-fold respectively (p<0.0001, Figure 3-9 A). Col10 content 
then decreased at week 8 by 72% and 92% (p<0.0001). However in PGH, only PHZ showed a 
significant increase in Col10 content at week 3 (15-fold, p= 0.0003); no significant change 
occurred at week 8 in both PHZ and HZ layers in PGH. Differences in the average Col10 content 
between hydrogel types became evident at the later time points. At week 3, the average Col10 
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content in the PHZ layer was 61% lower in PGH than in GEL at week 3 (p<0.0001. In contrast, 
the HZ layer in PGH showed significantly higher Col10 content at week 1 and week 8 compared 
to GEL (4.2-fold, p=0.0069, and 6.0-fold, p= 0.0109).  
Similar to Col2, Col10 deposition appeared more pericellular in PGH while farther 
distributed in GEL by week 3 and onward (Figure 3-8 and Figure 3-10). The concentration of 
Col10 deposition was higher in PGH than GEL for the PHZ and HZ layers at all time-points (p ≤ 
0.0112, Figure 3-9 B). No differences in concentration of Col10 deposition was detected for the 
PZ layer between hydrogel types. Similar to changes in the concentration of Col2 over time, the 
Col10 concentration in the PHZ and HZ layers in PGH decreased at week three by 33% 
(p=0.0002) and 26% (p=0.0003), respectively, as the average Col10 content by these populations 
increased, indicating diffusion of Col10 in PGH. However, the Col10 concentration increased at 
week 3 in the PHZ layer in GEL by 90% (p=0.0005) and subsequently plateaued. The Col10 
concentration for HZ remained stable in GEL.  
PGH delayed the deposition of Col10 by PHZ chondrocytes by at least one week 
compared to PHZ cell in GEL (Figure 3-8, Figure 3-9 C). Namely, the fraction of cells positive 
for Col10 was 11% for PHZ cells in PGH and 91% in GEL at week 1 (p<0.0001), and 93% for 
PHZ in PGH and 98% in GEL at week 3 (no significant difference). Although the fraction of 
Col10 positive PHZ cells in PGH caught up by week 3, the average Col10 content in PGH was 
still significantly lower. By week 8, the fraction of Col10 positive cells did not appear to change 
for PHZ cells in GEL but did significantly decrease in PGH by 54% (p<0.0001). In contrast for 
HZ cells, PGH consistently showed more Col10 positive HZ cells at all time-points (84% at week 
1, p<0.0001; 1.9-fold at week 3, p<0.001; and 1.6-fold at week 8, p=0.0006). The fraction of 





Figure 3-8 Col10 deposition by the different chondrocyte populations over 1, 3, and 8 weeks of growth in 
vivo in GEL (1-3, 7-9, 13-15) and PGH (4-6, 10-12, 16-18) hydrogel constructs. Immunostain green = Col10, 





Figure 3-9 Analysis of Col10 deposition in GEL and PGH hydrogel constructs by the different chondrocyte 
populations over 1, 3, and 8 weeks of growth in vivo. Average Col10 content (A), concentration of Col10 
deposition (B), and fraction of Col10 positive cells (C) were quantified by image analysis. *’’’ = p < 0.0001; 
*’’ = p ≤ 0.001; *’ = p ≤ 0.01; * = p < 0.05. Error bars = standard deviation of mean. 
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Figure 3-10 Distribution of Col 10 deposition by PHZ chondrocytes at 8 weeks of growth. Col10 (green) 




Likewise, PGH showed a higher area of ALP activity in the HZ layer at week 1 and week 
3 compared to GEL (13-and 14-fold, p<0.0001) (Figure 3-11). However, at week 8, the area of 
ALP activity decreased by 82% in PGH (p<0.0001), while more than quadrupled in GEL 
(p=0.0174), reaching similar levels between hydrogels with no significant difference. For the PZ 
and PHZ layers, there was no significant difference between hydrogel types at all time-points. 
The area fraction of ALP activity by PHZ significantly reduced between week 3 to week 8 by at 
62% (p=0.0019) in PGH and 72% (p<0.0001) in GEL (p≤0.0019). ALP staining was confined to 





Figure 3-11 Activity of ALP (BCIP stain) secreted by the different chondrocyte populations in GEL (A-C) 
and PGH (D-F) hydrogel constructs over 1, 3, and 8 weeks of growth in vivo (ALP activity = dark purple, 
counterstained with Fast Green). Area of ALP activity was quantified by image analysis (G). *’’’ = p < 
0.0001; *’’ = p ≤ 0.001; *’ = p ≤ 0.01; * = p < 0.05. Error bars = standard deviation of the mean. 
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3.3.4  Terminal Differentiation 
During endochondral ossification, terminally differentiated chondrocytes mineralize the 
extracellular matrix, with many undergoing apoptosis, to create calcified cartilage that is later 
remodeled into bone [87]. PGH inhibited mineralization by both PHZ and HZ cells, while GEL 
permitted mineralization by both as shown by Alizarin red (Figure 3-12A-F) and Von Kossa 
staining (Figure 3-12 G-L). In GEL, the PHZ and HZ layers showed increasing mineral deposition 
over time, by 36-fold (p= 0.0120) and 6.1-fold (p<0.0001) from week 1 to week 8, respectively, 
as indicated by Alizarin Red stain (Figure 3-13 A), and 6.7-fold (p=0.0111) and 5.5-fold 
(p<0.0001) by Von Kossa stain (Figure 3-13 B). Mineralization by PHZ was delayed relative to 
HZ, evident at week 3 as opposed to week 1. By week 8, 29.44 ± 17.16% of the PHZ layer stained 
for Alizarin red and 14.769 ± 8.869% for Von Kossa, while 92.84 ± 7.77% of the HZ layer stained 
for Alizarin Red and 80.229 ± 4.933% for Von Kossa. PZ cells never mineralized regardless of 
the hydrogel type, consistent with their lack of hypertrophy as shown by low Col10 deposition 
and ALP activity. In addition, there were significantly more apoptotic HZ cells in GEL compared 
to PGH at week 8 (86.9% ± 3.6% standard deviation versus 28.1% ± 1.1% respectively, p<0.0001, 





Figure 3-12 Mineral deposition in the different layers of chondrocyte populations in GEL and PGH hydrogel 
constructs over 1, 3, and 8 weeks of growth in vivo. GEL (A-C, G-I) and PGH hydrogels (D-F, J-L) by 
























































Figure 3-13 Area of mineral deposition was quantified by image analysis. A) Alizarin Red; B). Von Kossa.   
*’’’ = p < 0.0001; *’’ = p ≤ 0.001; *’ = p ≤ 0.01; * = p < 0.05. Error bars = standard deviation of the mean. 
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Figure 3-14 Apoptosis (DNA fragmentation) of the different chondrocyte populations in GEL (A-C) and 
PGH (D-F) hydrogels after 8 weeks growth in vivo. TUNEL stain (dark brown) = apoptotic cells. Arrows 
indicate examples of apoptotic cells. 
3.3.5  Alternate Phenotype Effects 
To further characterize the chondrocyte phenotype and investigate potential de-
differentiation, we analyzed Col1 deposition over time in vivo. Col1 is a matrix molecule present 
in locations such as the territorial matrix of hypertrophic chondrocytes, bone matrix, and 
fibrocartilage [83, 84, 88]. Col1 was present, albeit weak, in the day 17 chick sterna from which 
the chondrocyte populations were harvested (Figure 3-2). In general, PGH delayed the 






A). In PGH, no significant differences were found in average Col1 content over time until week 
8, when a marked increase occurred, by 3.9-fold for the PZ (p<0.0001), 4.4-fold for PHZ 
(p<0.0001), and 3.5-fold for HZ layers (p<0.0001, Figure 3-16 A). However, all populations in 
GEL showed an earlier increase in Col1 content at week 3, by 3.0- (p<0.0001) for the PZ, 4.6- 
(p<0.0001) for PHZ, and 2.0-fold (p=0.0451) for HZ layers. Subsequently at week 8 in GEL, the 
PZ layered plateaued while PHZ and HZ layers decreased in Col1 content (52%, p<0.0001 and 
71%, p=0.0397, respectively), consistent with mineralization of the latter. Comparing between 
hydrogel types, no significant differences in average Col1 content were apparent at week 1. By 
week 3, the PZ and PHZ layers in PGH showed 83% and 80% (p<0.0001) lower Col1 content 
compared to GEL. Yet by week 8, the PHZ and HZ layers showed greater Col1 content in PGH 
compared to GEL (1.2- and 9.2-fold, respectively, p<0.0001). Only PZ showed lower Col1 
content in PGH than GEL at week 8 (15%, p= 0.0034). Overall, the concentration of Col1 
deposition appeared higher in PGH than in GEL (Figure 3-16 B). Col1 concentration was 
significantly higher in PGH for the PZ and PHZ layers at week 1 (38%, p<0.0001, and 25%, 
p=0.0006). Only the PZ layer in PGH was significantly greater compared to GEL at week 3 (15%, 
p=0.0024), while both the PHZ and HZ layers in PGH at week 8 (23%, p=0.0006 and 21%, 
p=0.0034). The fraction of Col1 positive cells did not change for all three populations in PGH. 
However in GEL, the fraction of HZ cells positive for Col1 decreased 46% at week 8 (p<0.0001), 
consistent with greater apoptosis and high mineralization of the layer at this time; the fraction of 





Figure 3-15 Col1 deposition by the different chondrocyte populations over 1, 3, and 8 weeks of growth in 






Figure 3-16 Analysis of Col1 deposition in GEL and PGH hydrogel constructs by the different chondrocyte 
populations over 1, 3, and 8 weeks of growth in vivo. Average Col1 content (B), concentration of Col1 
deposition (C), and fraction of Col1 positive cells (D) were quantified by image analysis. *’’’ = p < 0.0001; *’’ 
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This work shows that hydrogel composition alone can regulate the maturation of 
chondrocyte populations. We tested populations that are similar to those which compose 
cartilaginous interfacial tissues such as the growth plate. Compared to the host mouse cells, the 
encapsulated chicken chondrocytes were morphologically different (smaller size, round shape). 
Therefore, it was unnecessary to label implanted chicken cells to distinguish them from the host 
cells. 
 Contrary to the effects of GEL (gelatin only hydrogel) on HZ cells (hypertrophic 
chondrocytes), the PGH (hydrogel composed of PEG, gelatin, and heparin) maintained GAG 
accumulation, decreased ALP activity, and inhibited mineralization by HZ cells out to two months 
growth in vivo, while maintaining to a large degree the deposition of collagens (Col1, Col2, 
Col10). These results indicate that PGH arrested maturation and terminal differentiation of HZ 
cells, retaining them in a GAG producing state. Early HZ (aka “upper part” of the hypertrophic 
zone in the growth plate) are highly matrix synthetic, expressing Col2, Col10, and aggrecan 
proteoglycan (consisting of GAGs covalently linked to a protein core) [10, 89]. It is not until the 
late HZ or terminal differentiation region (aka “lower part” of the hypertrophic zone) that 
aggrecan synthesis declines, while Col2 continues and ALP synthesis increases. In native chick 
sternum (day 17 incubation at which time cells were isolated), we found the highest GAG content 
at the cephalic region, not the medial or caudal regions, consistent with an early HZ phenotype.  
PGH promoted maintenance of HZ chondrocytes in an early hypertrophic state. After 
growth in vivo for 1 week, we found a significantly greater fraction of HZ cells in PGH were 
positive for GAG deposition compared to PHZ cells in PGH and HZ cells in GEL. We also 
observed a significantly greater area of GAG deposition by HZ cells in PGH compared to PHZ 
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cells in PGH and to all three populations in GEL (trend compared to PZ cells in PGH). However, 
the fraction of GAG positive HZ cells in PGH did significantly decline over time, approximately 
19% by week 8, and the area of deposition in the HZ layer in PGH was ultimately exceeded by 
the PZ layer regardless of hydrogel type. Nevertheless, the fraction of GAG positive HZ cells at 
week 8 was not significantly different from that of PHZ cells at all time-points in PGH. 
Concomitantly, we did not observe any change over time in the average Col2 content, consistent 
with the literature; only the concentration slightly decreased, likely due to further diffusion away 
from cells. Thus, these results support the conclusion that PGH facilitated maintenance of HZ 
cells in an early hypertrophic state. It is worthwhile to note that the phenotype of HZ cells in PGH 
also resembles chondrocytes in the deep zone of healthy articular cartilage, which also express 
high GAG and low Col2 protein, and do not mineralize [90]. Indeed, Col10 protein and ALP are 
detectable in articular cartilage, particularly the deep zone [91-93]. 
This study demonstrates a new multi-cell type, tri-layered in vivo model to evaluate 
scaffold effects on chondrocyte populations and scaffold suitability for the repair of cartilaginous 
tissues that interface with bone such as the growth plate repair. Layered hydrogel fabrication has 
been used to recreate the zonal organization and matrix properties of articular cartilage [90, 94, 
95]. However, these studies have not investigated the stability of the different articular 
chondrocyte phenotypes in engineered materials, specifically deep zone cells and their potential 
to undergo terminal hypertrophy and mineralization. In our work, we instead focused on growth 
plate-like chondrocyte populations, which do share some phenotype similarities with articular 
chondrocyte populations. We further employed a panel of matrix markers to characterize their 
phenotype in our hydrogel materials, including hypertrophy and matrix mineralization. Both PGH 
and GEL maintained the phenotype of PZ cells, evident by round cell morphology and production 
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of GAG and Col2. PGH and GEL also supported the maturation of PHZ and HZ cells, 
characterized by enlarged lacunae and pericellular Col10. However, PGH delayed maturation and 
inhibited terminal differentiation, while GEL was permissive for terminal differentiation and 
mineralization over a time-course that resembled the natural temporal profile in the chicken 
embryo [74, 96]. These results indicate that GEL is best suited for regenerating cartilages that 
mineralize or undergo endochondral ossification, such as the calcified zone of articular cartilage 
and the growth plate. This is of timely relevance to the field of cartilage regeneration, as GEL has 
been utilized for stem cell and chondrocyte based engineering of articular cartilage [97, 98], and 
is a popular bioink for bioprinting [65, 99]. Conversely, PGH is more suitable for scenarios where 
chondrocyte mineralization is undesirable, such as in the upper zones of articular cartilage and 
the resting zone of the growth plate.  
Though unique, the composition of PGH is similar to other composite hydrogels 
developed for cartilage regeneration. As noted in section 1.6, we selected the PEG component to 
resist cell-mediated contraction, gelatin to promote chondrocyte survival, and heparin to mimic 
the GAG matrix composition of growth plate cartilage. Addition of hyaluronan (a non-sulfated 
but acidic GAG) and chondroitin sulfate (a sulfated GAG) to gelatin hydrogels has been shown 
to enhance re-differentiation of human articular chondrocytes and cartilage matrix secretion in 
vitro over 8 weeks [100]. Likewise, the addition of these GAG to collagen hydrogels creates an 
interpenetrating polymer network that supports articular chondrocyte matrix deposition [101]. 
Composite hydrogels of gelatin and hyaluronan are in development for stem cell-based cartilage 
regeneration [102]. 
Furthermore, incorporation of heparin into gelatin hydrogels has been shown to increase 
GAG accumulation by chondrocytes derived from articular cartilage [103]. Heparin modified 
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PEG hydrogels have been investigated, albeit for osteogenesis [62]. Gelatin modified PEG has 
been shown to improve chondrogenic differentiation by mesenchymal stem cells compared to 
PEG only hydrogels under chondrogenic conditions in vitro [40]. A three-part composite hydrogel 
composed of acrylated PEG, thiol-modified gelatin, and thiol-modified hyaluronan is 
commercially available (HyStemTM, ESI BIO); however, it relies on different crosslink chemistry 
and little work has investigated its utility for cartilage regeneration [104]. Numerous other 
hydrogel formulations exist for cartilage engineering, including blends of several GAGs and 
polysaccharides, or single GAGs alone [105, 106]. We selected heparin over other GAGs because 
hyaluronan is not sulfated, and because chondroitin sulfate is less electronegative and has lower 
affinity for chondrogenic growth factors [107, 108]. Instead, heparin promotes signaling of 
numerous growth factors produced by chondrocytes, including transforming growth factor β-1 
(TGFβ-1) [41-47]. As such, it can potentiate and interfere with autocrine cellular signaling. 
Affinity-based selection of alternate heparan sulfated GAGs with desired growth factor binding 
properties may provide a more targeted approach [109]. Nevertheless, no prior study with 
hydrogels has shown that they can inhibit terminal differentiation and mineralization by 
chondrocytes, as shown here.  
Through control over chondrocyte phenotype, these photocrosslinkable hydrogels are of 
potential utility in engineering the complex cellular architectures of interfacial cartilages, 
particularly for regeneration in situ. For example, maintenance of chondrocyte phenotypes and 
protection from premature hypertrophy may facilitate the reestablishment of the interzonal 
signaling that orchestrates cell proliferation and maturation in the growth plate, and subsequently, 
restore normal endochondral ossification and bone growth. Hydrogels can be micropatterned to 
replicate the cellular architecture of the growth plate. Numerous techniques exist to create multi-
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layered hydrogels with different biological functions in the layers (e.g., cell populations, drug-
eluting microparticles, matrix molecules, stiffness gradients); for a review, see Liu et al. 2018 
[110]. Cell sourcing and expansion issues limit the translation potential of patterning of different 
cell populations. More readily translatable approaches require delivery of spatial cues to guide 
the differentiation of progenitor cells in situ. However, the mechanoactive environment in situ 
engenders interstitial fluid flow that disrupts the spatial distribution of growth factors eluted from 
delivery vehicles embedded in hydrogels [41]. Therefore, we have focused on developing scaffold 
materials to guide cell differentiation and phenotype. The matrix molecules of the GEL and PGH 
hydrogels are insoluble by nature of their crosslinking and remain in place until degraded, 
presumably by which time the cellular architecture would be restored and self-sustained by 
endogenous matrix and intercellular signaling. Such an approach has not been adopted for growth 
plate regeneration.  
It is important to note that these chick sternal chondrocyte populations, though similar in 
phenotype, are derived from a different developmental lineage than chondrocyte populations in 
the growth plate, and are subject to different epigenetic regulation. In our study, all cell 
populations expressed Col1 in vivo, with a strong cytoplasmic signal throughout the study, but 
with a faint extracellular signal detectable only at the later time points. Though the change over 
time in the Col1 content within the territorial matrix appeared large, it is important to note that 
the content measured was normalized to the HZ layer in GEL at week 1, which had very low 
signal. The absolute signal intensity increase was low, and staining remained faint throughout. It 
is unlikely that the source of extracellular Col1 was fibroblasts in the fibrous capsule and fascia 
which surrounded the implant, as the faint staining appeared stronger in the pericellular rather 
than territorial matrix. In the growth plate, Col1 has been detected intracellularly in hypertrophic 
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chondrocytes [111], and the territorial matrix of the “lower” hypertrophic zone (late hypertrophic 
chondrocytes) [84]. Col1 is also expressed in the perichondrium, osteoid, and new bone of [86, 
112]. The strong cytoplasmic Col1 expression in HZ and PHZ cells is consistent with that of 
hypertrophic chondrocytes in the growth plate, including the prehypertrophic cells that become 
hypertrophic. However, Col1 expression by the PZ cells is not consistent with proliferative cells 
of the growth plate. In addition, Col1 expression in the chick sternum has not been reported [49]. 
However, in our study, we did observe weak Col1 expression in the native chick sternum by all 
three chondrocyte populations (Figure 3-2). Together with the continued GAG and Col2 
expression, this likely excludes de-differentiation (from prolonged growth in an ectopic site) as a 
potential cause for Col1 expression by PZ [100, 113, 114]. It is possible that PZ were pushed to 
a more perichondrium-like phenotype, which includes expression of Col1, Col2, and GAG 
(namely aggrecan) [115], or that chick Col1 expression is another difference between avian and 
mammalian species [116].  
The cellular mechanisms underlying the hydrogel effects on chondrocyte phenotypes have 
not been investigated in this study. Both hydrogels types had insignificant vascular invasion 
across all layers, precluding uncoupling of angiogenesis as the inhibitor of terminal hypertrophy 
and mineralization [70]. The unique composition of PGH may directly interfere with 
mineralization, provide matrix ligand and mechanical cues to directly alter phenotype, and/or bind 
endogenous growth factors to indirectly alter autocrine/paracrine signaling. Regarding physical 
inhibition of mineralization, the content of heparin in PGH is well above that shown to inhibit 
aggregation of hydroxyapatite crystals in vitro [50]. The incorporation of heparin into fixed 
tissues (bioprosthetic heart valves) can inhibit calcification [117]. The heparin component may 
affect the transport of anionic species required for mineralization (as opposed to binding of 
 65 
calcium [118, 119]), namely phosphate. The continued GAG deposition by HZ and PHZ cells in 
PGH may also have physically inhibited hydrolysis of pyrophosphate by ALP [120] and thereby 
mineral nucleation and growth [119, 121]. Furthermore, PGH may have retained fewer matrix 
vesicles secreted by HZ and PHZ cells than GEL, due to differences in Col2 and Col10 content 
[11, 122, 123].  
Regarding mechanical cues, the lower relaxation modulus of PGH compared to GEL is 
unlikely to drive the observed effects. Chondrocytes are mechanosensitive, and their phenotype 
can be altered by substrate stiffness and mechanical stress [57, 58]. 
No apparent differences in cell morphology were evident between the GEL and PGH 
hydrogels at week 1. Yet HZ cells in PGH showed greater RhoA gene expression than in GEL 
after culture for one week (not shown), though the PGH relaxation modulus (described in Aim 1) 
was lower. We speculate that the greater gelatin content and stiffness in GEL inhibited integrin 
receptor clustering and formation of focal adhesion complexes compared to PGH.  
Regarding cell signaling, the effects of direct signaling by the hydrogel polymers are likely 
most evident at the early time point, as pericellular matrix deposition changes the ligand milieu. 
The gelatin polymer is a substrate for integrins αvβ3 and α5β1. Blocking of β1 integrin signaling 
decreases Col10 production and hypertrophic differentiation in organ explant cultures of chick 
sterna [79]. Targeted antagonism of α5β1 integrin decreases Col2 and Col10 expression decreases 
apoptosis and inhibits differentiation of prehypertrophic chondrocytes in embryonic mouse limbs 
(exo utero and in limb organ cultures) [124, 125]. This is consistent with the lower Col2 and 
Col10 deposition at week 1 by PZ and PHZ cell sin PGH, which contains about 5x less gelatin 
than GEL. However, this does not explain the higher Col10 deposition by HZ cells in PGH than 
in GEL at week 1, and the inhibition of terminal differentiation and mineralization by HZ cells 
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throughout. Instead, PGH may inhibit terminal differentiation by binding and promoting signaling 
of endogenous growth factors which hinder hypertrophy and terminal differentiation, such as 
Fibroblast growth factors (FGFs) [2, 126, 127], IHH [2], and TGFs [128-131]. Specifically, the 
heparin component of PGH interacts with these growth factors [46, 74, 132-136]. Inconsistent 
with our results, heparin has been found to decrease total collagen synthesis as well as type X 
collagen production by embryonic chicken chondrocytes[137]. Future work is needed to 
investigate the intracellular signaling mechanism underlying the inhibition of terminal 
differentiation and mineralization, particularly the Wnt/β-catenin pathway which is a key 
regulator of hypertrophy and endochondral ossification [138, 139]. 
In this present work, the three chondrocyte populations were encapsulated respectively in 
three neighboring hydrogel layers of the same construct rather than in three separate hydrogel 
constructs containing a homogenous cell population. This design mimicked the cellular 
organization of native growth plate and allowed us to analyze the phenotypes of chondrocytes 
when they were adjacent to cells at other differentiation stages. Image-based quantitative analysis 
of protein deposition was used because the individual layers could not be repeatably separated 
from the tri-layered constructs for reliable biochemical analysis. Such approach is a low-cost 
alternative and has been described by Kirkeby et al.in 2005 [140]. It is worth noting that the 
image-based analysis of histochemical stains (GAG, Alizarin Red, Von Kossa, and ALP activity) 
may not be as accurate as a biochemical method. Accuracy of the analyses is also sensitive to 
section thickness. We were careful to analyze sections of the same thickness (10 µm) and stained 
at the same time and for the same duration. We cannot fully characterize the precise phenotype 
of the chondrocyte populations using our limited but specific biochemical and antibody marker 
panel. This will require RNA sequencing and proteomics approaches. Future work is necessary 
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to elucidate the material and molecular mechanisms driving the hydrogel effects. This includes 
investigation of ratio of phosphate to pyrophosphate (a potent inhibitor of crystal growth), matrix 
vesicle secretion by chondrocytes [141], the composition and crystal structure of mineral 
deposited, the effect of substrate stiffness on cytoskeletal structure and focal adhesion complex 
(FAC), and potential changes in hydrogel stiffness during culture in vivo to understand 
mechanotransduction effects. It will also be interesting to determine if PGH will inhibit 
mineralization by osteoblasts or by HZ cells under thyroid hormone stimulation [142]. 
3.5 Conclusion 
This work shows that hydrogel composition alone can regulate the maturation of growth 
plate-like chondrocyte populations. Compared to GEL (gelatin hydrogel), PGH (composite 
hydrogel) maintained GAG production by HZ cells (hypertrophic chondrocytes), arrested 
terminal differentiation, and inhibited mineralization. Through control over chondrocyte 
phenotype, the PGH hydrogel is of potentially critical utility in engineering the complex cellular 
architectures of the growth plate in situ. 
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4.0 Specific Aim 3: Evaluate the Effects of the PGH Hydrogel on Stem Cell 
Chondrogenesis and Osteogenesis In Vitro and In Vivo 
4.1 Introduction  
Hydrogels are very popular because they can mimic the hydrophilic matrix composition 
of cartilage, carry cells and drugs, and promote chondrogenesis, with novel studies seeking to 
develop biocompatible hydrogels that mimic cartilage compressive stiffness [143]. Yet the loss 
of chondrocyte phenotype remains a problem in the regeneration of hyaline cartilage, whether 
progression to hypertrophy or dedifferentiation into fibroblast-like cells [144, 145].  Bone 
marrow-derived mesenchymal stem cells (BMSCs) are a viable cell source for regeneration 
because they can be driven down multiple lineages, including cartilage. Indeed, commercial 
products exist that employ autologous BMSCs for cartilage regeneration [146]. However, the 
phenotype of BMSC derived chondrocytes is unstable, progressing to terminal hypertrophy and 
tissue mineralization¸ which ultimately leads to endochondral ossification [147-151]. Other 
mesenchymal stem cell (MSC) sources, such as adipose or synovial, also suffer hypertrophy or 
unstable phenotype [152, 153]. Recent work has identified chondroprogenitor cells within 
cartilage, which express lower levels of hypertrophy markers when cultured in hydrogels [154]. 
However, cell sourcing and expansion issues limit their applicability for cartilage engineering 
compared to BMSCs. In this light, a need exists for hydrogels that promote stable chondrogenic 
differentiation of BMSCs.  
Moreover, hydrogels are needed that can control BMSC differentiation down multiple 
lineages to regenerate the cellular architecture of the growth plate cartilage. Multiple materials 
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and scaffold assembly approaches, including hydrogel bioinks and solid free form fabrication 
technologies, have been advanced to promote development of the natural layered cellular 
architecture of interfacial tissues, as well as osteochondral tissues, including discrete 
printing/encapsulation of different cell types or growth factors and multi-part scaffold assembly 
[68, 155-159]. Studies have attempted to guide BMSC differentiation in situ to recapitulate the 
cellular architecture [160, 161]. However, instability of the chondrocyte phenotype and 
uncontrolled differentiation down alternate lineages remain a difficulty. 
To work towards regeneration of growth plate cartilage with BMSCs, this work sought to 
develop a photopolymerizable hydrogel to overcome these limitations, namely to drive BMSC 
chondrogenesis in situ without aberrant osteogenesis or mineralization.  
The objective of this study was to characterize the PGH hydrogel and evaluate its effects 
on chondrogenesis and osteogenesis by BMSCs compared to the GEL-MA only hydrogel (GEL), 
which served as a control used for chondrogenic and osteogenic differentiation by BMSCs [154, 
162]. We evaluated BMSC differentiation and growth in the hydrogels in vitro using cultures with 
chemically defined mediums, and in vivo, using implantation of scaffolds in subcutaneous pockets 
in immunocompromised mice. 
4.2 Materials and Methods 
4.2.1  Materials 
PEGDA, GEL-MA, HEP-MA, and LAP were synthesized as described in section 2.2.2. 
Cell culture supplies were purchased from Atlanta Biologicals (Flowery Branch, GA) and Thermo 
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Fisher Scientific (Waltham, MA). Transforming growth factor beta-3 (TGFβ-3) was purchased 
from R&D Systems (Minneapolis, MN). The 16G Jorvet bone marrow needle was purchased 
from Henry Schein Animal Health (Melville, NY). Ficoll-Paque PLUS and other stem cell 
isolation supplies were purchased from Thermo Fisher Scientific. The Von Kossa Stain Kit was 
purchased from American MasterTech (Lodi, CA). Primers were synthesized by Integrated DNA 
Technologies (Coralville, IA). Immunocompromised mice, NOD.CB17-Prkdcscid/SzJ, were 
obtained from Jackson Laboratory (Bar Harbor, ME). Spanish goats were purchased from K-Bar 
Livestock, LLC (Sabinal, TX).  
 
4.2.2  BMSCs Isolation and Culture 
Human BMSCs (hBMSC) and expansion medium were purchased from RoosterBio, Inc 
(Frederick, MD). Goat BMSC were isolated from bone marrow aspirates drawn from the iliac 
crests of 3-month-old female Spanish goats using 16G bone marrow biopsy needles and 10mL 
syringes loaded with 3 mL α-MEM medium containing 180 U/mL heparin. Erythrocytes were 
removed via Ficoll-Paque PLUS following the manufacturer’s protocol. The mononuclear cells 
were plated and goat BMSCs isolated as tissue culture adherent cells. Both human and goat 
BMSCs were expanded for three passages (1 week each) for experimental use. Cells were cultured 
until 80% confluence, trypsinized, and plated at 7.5×105 cells per 175 cm2 cell culture flasks.   
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4.2.3  Hydrogel Fabrication 
The hydrogel solutions were prepared by dissolving the modified polymers at 10% (w/v) 
in PBS and adding 0.01% (w/v) LAP. The PGH hydrogel was composed of PEGDA, GEL-MA, 
and HEP-MA at a 63:21:16 mass ratio. The GEL was composed of only GEL-MA. The prepared 
solutions were then mixed with human or goat BMSCs at 30 million/mL, cast in silicone molds 
as 2 mm thick sheets, and photocrosslinked with 2.5 J/cm2/mm UV-A light (365 nm) for 3.5 
minutes. Cylindrical hydrogel constructs were cut using 5 mm biopsy punches.  
4.2.4  Material Effects on BMSCs In Vitro  
To select BMSCs with potential to undergo chondrogenesis, cells from several goats were 
screened in a standard pellet culture over 6 weeks in chemically defined chondrogenic medium. 
Chondrogenic medium consisted of Gibco high glucose DMEM, ITS 1/100X, 100 μM L-ascorbic 
acid 2-phosphate, 100 nM dexamethasone, 40 μg/mL L-proline, 10 ng/mL TGFβ-3, and 0.1 mM 
non-essential amino acids. Three donors were selected with histological evidence of 
chondrogenesis (GAG staining) and used for replicates of the following experiments. To evaluate 
the hydrogel material effects under controlled conditions, scaffold cylinders were cultured in 
either osteogenic medium or chondrogenic medium for 6 weeks (n = 3 for each hydrogel type and 
culture medium). Osteogenic medium consisted of Gibco GLUTAMAX αMEM, 10% fetal 
bovine serum, 1% P/S, 10 nM dexamethasone, 5 mM β-glycerolphosphate, 50 µM L-ascorbic 
acid 2-phosphate.  Following 6 weeks, the scaffolds were analyzed with histology for the presence 
of GAG and mineral.  
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4.2.5  Material Effects on BMSCs In Vivo 
The PGH and GEL we loaded with pooled hBMSCs from two patients and with 50 ng/mL 
TGFβ-3 before crosslinking. The hydrogel cylinders were implanted in dorsal subcutaneous 
pockets in 5-week-old male mice under IACUC approval (n= 6 per scaffold type, 11 mice total). 
Briefly, two incisions were made cranial and caudal along the midline and pockets opened to the 
left and right using a blunt-tipped scissors. After placing the scaffold, incisions were closed with 
surgical clips. The animals were sacrificed at 8 weeks, and the constructs collected for analysis. 
The tissues were processed for cryosectioning, which entailed immersion in 30% (w/v) sucrose 
in PBS overnight followed by 40% (v/v) O.C.T. Compound (Thermo Fisher) in PBS for two days, 
followed by snap freezing and embedding in O.C.T. GAG deposition was detected by Safranin O 
staining (with Fast Green counterstain) and the percent of GAG positive cells was calculated 
(number of cells surrounded with GAG  total number of cells). Minerals were detected by Von 
Kossa staining. Chondrogenic and osteogenic gene expression was analyzed by real-time 
polymerase chain reaction (PCR) for cartilage markers aggrecan (AG) and collagen type II 
(COL2), for the hypertrophic marker collagen type X1 (COL10), and the osteogenic marker bone 
sialoprotein-II (BSP) using our published primers [163].  RT-PCR results were calculated relative 
to the GEL, normalized to GAPDH expression, and plotted as “proportional fold change” to 
facilitate graphical interpretation, where increases are fold change minus 1.0 (i.e., 2-ΔΔCT-1), 
decreases are the inverse of fold change minus 1.0 (i.e. -(2ΔΔCT-1), and no change reads as 0.0. 
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4.2.6  Statistical Analysis 
Results are expressed as mean ±  standard deviation (SD). Significant differences in gene 
expression (PCR) were detected at anα=0.05 using t-tests on the ΔΔCT values (normally 
distributed). 
4.3 Results 
4.3.1  Effect of PGH and GEL on Chondrogenesis and Osteogenesis In Vitro 
Chondrogenesis was seen in both the PGH and the GEL in chondrogenic medium (Figure 
4-1 A, B, respectively), with staining confined to the pericellular region and staining intensity 
stronger in the GEL (n=3 per scaffold). No evidence of GAG staining was found for scaffolds 
cultured in osteogenic medium (Figure 4-1 C, D). Signs of osteogenesis was only observed in the 
GEL in the osteogenic medium, as evidenced by mineralization staining (Figure 4-2 D). No Von 
Kossa staining was evident in the PGH (Figure 4-2 C). No sign of mineralization was observed 





Figure 4-1 Safranin-O staining of PGH and GEL hydrogels containing goat BMSCs after in vitro culture. (A, 






Figure 4-2 Von Kossa staining of PGH and GEL hydrogels containing goat BMSCs after in vitro culture. (A, 
B) Culture in chondrogenic medium. (C, D) Culture in osteogenic medium. Scale bar = 100 µm. 
4.3.2  Effects of PGH and GEL on hBMSCs Differentiation In Vivo 
Histology at 8 weeks revealed that with a single supplement of TGFβ-3 (supplemented 
into the hydrogel during fabrication), hBMSCs underwent chondrogenesis in both the PGH and 
the GEL (Figure 4-3 A, B). The cartilage formation was not robust, as indicated by the focal 
pericellular Safranin O staining. The GAG stain appeared more intense in the GEL than PGH. 
However, the PGH seemed to show a greater percent GAG positive cells (68 ± 4.3%) compared 
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to the GEL (48 ± 4.4%) as evidenced by Safranin O staining (Figure 4-4 B).  hBMSCs in PGH 
expressed 9.4 fold higher type II collagen and 2.8-fold higher aggrecan after 8 weeks compared 
to in GEL as shown via PCR (Figure 4-4 A), confirming the percent of GAG positive cells. In 
addition, the PGH showed less fibrous tissue than the GEL, as indicated by Fast Green staining. 
Von Kossa staining showed the presence of phosphate and calcium only in GEL hydrogels (Figure 
4-3 C, D). Consistent with histology, expression of type X collagen and bone sialoprotein in PGH 







Figure 4-3 Histological staining of PGH and GEL hydrogels containing human BMSCs after 8 weeks of 
growth in subcutaneous pockets in immunocompromised mice. Safranin O staining of PGH (A) and GEL 





Figure 4-4 Quantification of human BMSC gene expression and GAG staining in PGH and GEL hydrogels 
grown for 8 weeks in mice. (A) Quantitative PCR analysis.  PGH expressed 9.4 fold higher type II collagen 
and 2.8 fold higher aggrecan compared to in GEL. Expression of type X collagen and bone sialoprotein in 
PGH were 8.4% and 1.7% of that in GEL, respectively. (B) Fraction of cells staining for GAGs in their 
pericellular matrix. (* p<0.01). 
4.4 Discussion 
These results revealed that the PGH hydrogel appeared to promote chondrogenic 
differentiation of BMSCs while inhibiting osteogenic differentiation, while the conventional 
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gelatin hydrogel (GEL) is permissive to both chondrogenic and osteogenic differentiation. The in 
vitro assays with goat BMSCs showed that while permitting chondrogenesis the PGH did not 
support mineral deposition in an osteogenic environment, suggesting a lack of osteogenic 
differentiation. The results were supported by the in vivo study where the PGH had greater 
potential to induce chondrogenesis by human BMSCs than the GEL, evidenced by the elevated 
expression of aggrecan and type II collagen and a higher fraction of GAG positive cells after 8 
weeks growth. However, the weak GAG deposition after 8 weeks growth in vivo showed that 
one-time dosing of TGFβ-3 in the hydrogels was ineffective in inducing rapid stem cell 
chondrogenesis, likely due to diffusion and loss of the growth factor. The in vivo study also 
suggested that PGH is anti-osteogenic, supported by the lack of mineral staining and biologically 
meaningful collagen type Xα1 and bone sialoprotein gene expression.  
The PGH hydrogel is a potentially useful biomaterial for stable hyaline cartilage 
engineering and the regeneration of cartilaginous interfaces. The hydrogel itself supported 
hBMSC chondrogenesis in vivo while preventing chondrocyte hypertrophy (Collagen Type Xα1) 
and mineral deposition (Von Kossa). Hypertrophy is a well-known but often overlooked concern 
for cartilage regeneration using stem cells, especially for stable hyaline cartilage, where 
mineralization is undesirable [164]. Studies have investigated means to inhibit BMSC derived 
chondrocyte hypertrophy, such as modulating the scaffold stiffness [67], dynamic compressive 
loading of constructs [150, 165], incorporation of matrix molecules and soluble biofactors that 
modulate intracellular signaling pathways of hypertrophy [149, 151, 166], gene-level 
intervention, co-culturing with articular chondrocytes, lowering oxygen tension, and modification 
of culture substrates [167].  Among the approaches above, modulating the culture substrate or 
scaffold is most feasible for translation to clinical therapy. The mechanisms of the PGH effect on 
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chondrogenesis and mineralization are elusive. The heparin component is unique among the 
sulfated GAGs in its high binding of numerous growth factors [44-47]. Heparin is structurally 
similar to heparan sulfate (HS); HS-containing proteoglycans are co-receptors for over 200 
proteins [168]. Heparin may preferentially sequester those that promote osteogenesis (e.g., BMP-
2) [169] through binding and potentiation of endogenously secreted anti-osteogenic growth 
factors [41-47]. In addition, the highly anionic nature of heparin is similar to that of cartilage. At 
the concentrations in PGH, heparin may impact the transport of anionic species required for 
mineralization (as opposed to binding of calcium) [118, 119], namely phosphate in vivo and β-
glycerophosphate in vitro, ergo in part why these are packaged within matrix vesicles of 
mineralizing cartilages [141]. Heparin has been shown to inhibit aggregation of hydroxyapatite 
crystals in vitro [170], and calcification of prosthetic heart valves [117]. Altered matrix 
mineralization may in turn impact progression of the hypertrophy in BMSC derived chondrocytes, 
and the ability of BMSCs to undergo osteogenesis, e.g., calcium and phosphate signaling. In this 
manner, incorporation of highly sulfated molecules such as heparin may be beneficial compared 
to incorporation nonsulfated polysaccharides such as hyaluronan [68]. Thus, the amount of 
heparin in the PGH hydrogel may be key for the observed anti-hypertrophic and anti-osteogenic 
effects of PGH. 
By nature of their composition alone, the PGH and GEL hydrogels regulated BMSC 
differentiation down the different osteochondral lineages. To understand the effect of hydrogels 
on BMSC chondrogenesis, longer time course studies such as this are needed that investigate the 
phenotype stability of differentiated BMSCs [171]. As such, they can be applied to regenerate 
tissue for joint resurfacing in situ, without the need for predifferentiation of stem cells, discrete 
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encapsulation of different cell types or growth factors, multi-part scaffold assembly, and complex 
bioreactor systems [68, 155-158].   
To control the spatial organization of tissue formation, many multilayer scaffold designs 
have been tested for the regeneration of the tendon/ligament enthesis (bone-cartilage-ligament 
interface) [172-177].  These works have focused on the high mechanical demands of these 
interfaces.  Zhu et al. have developed gradients of mineral to anchor their trilayer designs [173].  
Lee et al. instead have developed polymers, including nanofibers, of differing properties to 
withstand in-situ forces [175].  Since the growth plate cartilage does not experience tensile forces 
as do tendons and ligaments, a different approach is required for growth plate regeneration, with 
materials that perform well under compressive loads such as hydrogels.  We believe that the PGH 
hydrogel can be used to regenerate the growth plate cartilage.  
Future work will further investigate the mechanisms of phenotype stability of BMSC 
derived chondrocytes, including culture conditions that promote hypertrophy and mineralization.  
4.5 Conclusion 
Our in vitro experiment has suggested the inhibition of osteogenesis and maintenance of 
chondrocyte phenotype by BMSCs in a PGH hydrogel. This effect was confirmed with in vivo 
growth experiments over two months. Compared to GEL, the PGH hydrogel seemed to support 
stem cell chondrogenesis and cartilage matrix production while inhibiting direct osteogenesis, 
hypertrophy, and mineral deposition. The PGH hydrogel is a promising material to regenerate 
growth plate cartilage.  
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5.0 Specific Aim 4: Assess the Efficacy of the Stem Cell-laden PGH Hydrogel in Cartilage 
Regeneration and Bony Tether Prevention in a Growth Plate Injury Model in 
Goats 
5.1 Introduction 
Growth plate injury is a significant pediatric orthopedic problem; 15% of long bone 
fractures in children involve the growth plate, with a 35% prevalence in 10 to 15-year-old 
children. The overall incidence of growth plate injury in the juvenile population is 2.4 to 4.6 per 
1,000 [178-183]. Up to 75% of these physeal injuries cause some growth disturbances, most often 
from the bony tethers bridging the epiphysis and metaphysis. In the lower limbs, tethers cause 
angulation deformity, length discrepancy, and substantial physical impairment. Surgical 
procedures are available to correct these deformities. However, they are associated with a number 
of disadvantages [9, 184]. For example, distraction osteogenesis is highly invasive, painful, and 
prolonged (3-6 months) [9]. Epiphysiodesis (hardware implantation and/or physeal bar 
rotation/excision to restrict growth) sacrifices patient height and is often followed with an 
osteotomy to reshape geometry or distraction to restore length [185]. The Langenskiold procedure 
(autologous transplant of fat as an interpositional material) has a high risk of bony tether 
recurrence [25]. 
Currently, there is no biological therapy available to regenerate the growth plate cartilage 
and prevent bony tether formation simultaneously [12]. Regenerative approaches have been under 
investigation for decades. By using a combination of stem cells, growth factors, and scaffolds as 
the interpositional material, some success has been reported in rabbits; nevertheless, such 
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treatment has not succeeded in large animals [9, 29, 30]. Large animals are better models for 
studying growth plate repair due to their relatively comparable size to humans. Besides, growth 
plates of smaller animals are very different from those of humans; rabbits have little cancellous 
bone in the metaphysis; cycle time of rat proliferative chondrocytes is twenty times faster than 
human [4, 12, 186].  
In Aim 2, we have demonstrated that compared to GEL-MA only hydrogels, PGH 
hydrogel inhibits mineralization and osteogenesis while supports chondrogenesis by BMSCs. 
In this portion of the work, we evaluated autologous BMSC-laden PGH hydrogels in a 
goat model for growth plate cartilage regeneration and bony tether prevention. We also tested tri-
layered PGH hydrogels with the top layer supplemented with human parathyroid hormone (PTH) 
(1-34) and the bottom layer supplemented with triiodo-L-thyronine (T3), in an attempt to 
differentiate stem cells in these layers into proliferative and hypertrophic chondrocytes 
respectively. Our previous studies have shown that PTH (1-34) stimulates chondrocyte 
proliferation and inhibits hypertrophic differentiation; T3 induces hypertrophic phenotypes, up-
regulating type X collagen, and alkaline phosphatase activity. 
5.2 Materials and Methods 
5.2.1  Materials 
PEGDA, GEL-MA, HEP-MA, and LAPwere synthesized as described in Section 2.2.2. 
Cell culture supplies were purchased from Atlanta Biologicals (Flowery Branch, GA) and Thermo 
Fisher Scientific (Waltham, MA). Recombinant human transforming growth factor beta-1 (TGFβ-
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1) was purchased from Peprotech (Rocky Hill, NJ). Human parathyroid hormone (PTH) (1-34) 
was purchased from Fisher Scientific. Triiodo-L-Thyronine (T3) was purchased from Sigma-
Aldrich. Goat BMSCs were obtained as described in Aim 3. Ultra-clear PFA tubing, 4.5 mm drill 
bits, drill collars, and oil-resistant Buna-N rubber sheet were purchased from McMaster 
(Elmhurst, IL). Paraformaldehyde and chemicals to make phosphate buffered saline were 
obtained from Sigma-Aldrich. Immunocal® solution and disposable biopsy punches were 
purchased from Fisher Scientific. Spanish Boer goats were purchased from K-Bar Livestock, LLC 
(Sabinal, TX). Drill guide, Kirschner-wires, and other surgical tools were purchased from Synthes 
(Raynham, MA). Anti-RANK antibody [64C1385] (ab13918) and Methyl Green Pyronin Stain 
Kit (RNA DNA Stain) (ab150676) were purchased from Abcam (Cambridge, United Kingdom). 
5.2.2  Hydrogel Fabrication 
Goat BMSCs were plated the day before surgery to recover from cryo-storage overnight, 
then trypsinized and encapsulated in hydrogels on the day of surgery. Hydrogel solution was 
prepared by dissolving the modified polymers at 8% (w/v) in PBS and adding 0.01% (w/v) LAP 
(photoinitiator). The PGH hydrogel was composed of PEGDA, GEL-MA, and HEP-MA at a 
63:21:16 mass ratio. The prepared solution was mixed with TGFβ-1 at 10 µg/mL and goat BMSCs 
at 30 million/mL. Two groups of hydrogels were fabricated. The homogenous group was cast in 
a 15 mm long Ultra-Clear PFA tube (4 mm inner diameter) and photocrosslinked with 2.5 
J/cm2/mm UV-A light. For the tri-layered group, the solution was divided into three separate 
tubes, one supplemented with PTH (1-34), one un-supplemented, and the third supplemented with 
T3. Three different molds were used for casting.  A straight cut was made on a 15 mm PFA tube 
at 1/3 diameter, along the longitudinal plane, by using a razor blade. The shallow part was mold 
 85 
A, and the deeper was mold B. A 2 mm high, 4 mm diameter rubber stopper was placed at one 
end of each mold to prevent leakage of the polymer solution. The bottom layer was cast first in 
mold A, using the T3 hydrogel solution. Crosslinking was performed as described above. The 
rubber stopper was then removed, and the hydrogel was pushed into mold B and placed at the 
bottom. TGFβ-1 only hydrogel solution was added on top of the bottom layer, filling mold B, 
then crosslinked. Following the crosslinking, the stopper was removed, and the bi-layered 
hydrogel was pushed into an uncut 15 mm tube and place at the bottom. The last mode was filled 
with PTH (1-34) hydrogel solution and exposed under the UV light to make the top layer. The 
hydrogel was then ready for implantation. 
5.2.3  Surgical Procedures  
In total, the growth plates in hind legs of 8 Spanish Boer goats (3-month-old females) 
were operated bilaterally (n=16 defects), under an IACUC approved protocol at the University of 
Pittsburgh. The defects were divided into the following experimental groups: homogenous 
hydrogel (n=4), tri-layered hydrogel (n=9), and untreated control (n=3). The animals fasted for 
36 hours before surgery. A combination of ketamine (5 mg/kg) and xylazine (0.1 mg/kg) was 
used for anesthesia. Throughout the surgery, isoflurane was given by inhalation (2-3%). 
Ketoprofen was given intraoperatively via intravenous administration (1 mg/kg). A medial 
approach to the proximal tibial plateau was taken to locate the growth plate. The soft tissue was 
dissected, and a pin was inserted at the posterior aspect of the growth plate. The posterior 
placement was selected to avoid the undulation of the growth plate in the anterior region. A digital 
X-ray was taken by using a FIDEX Multi-Modality Veterinary scanner (Animage, Pleasanton, 
CA) to confirm that the pin was inserted at the growth plate margin. The angle of the drill was 
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calculated to follow the growth plate in a mediolateral direction. A 1 mm drill guide was inserted 
to a depth of 20 mm. Then, a 4.5 mm diameter hollow drill was used to create a defect with a 
depth of 15 mm. The defect was irrigated copiously with saline. Then, a solid metal rod of 4.5 
mm was inserted to occupy the space and promote clotting. After 10 minutes, the hydrogel 
implant was inserted into the defects from the PFA tubes using a metal plunger. Kirschner wires 
were inserted in the epiphysis, metaphysis, and diaphysis of the proximal tibia to track bone 
growth throughout the study. The soft tissue was first sutured, followed by the fascia and then the 
overlying skin. An injection of antibiotics (ceftiofur, 5 mg/kg) was given. Following the surgery, 
the animals were allowed to bear weight. The animals were sacrificed at three months by 
administering Buthanasia intravenously (1 cc/10 kg). The proximal tibias were collected for 
analysis.  
5.2.4  Histology Analysis 
Computed tomography (CT) images of the tibia were taken by using the FIDEX scanner 
to assess the growth plate repair and bony tether formation. The samples were cut into 
approximately 3 × 3 × 3 cm blocks and fixed with 4% (w/v) formaldehyde solution for seven 
days. Samples were then decalcified in Immunocal® for seven days; decalcification was 
confirmed by X-ray. Following decalcification, the samples were cut in halves, along the plane 
of the defect. They were then immersed in 30% (w/v) sucrose solution overnight, 40% (v/v) 
optimal cutting temperature compound for two weeks, and cryosectioned at a thickness of 10 µm. 
Two sets of stains were performed, hematoxylin/eosin, and safranin O/Fast Green/hematoxylin. 
Anti-RANK antibody [64C1385] (ab13918) was used to immunostain the receptor activator of 
NF-κB (RANK). Methyl Green Pyronin Stain Kit (RNA DNA Stain) (ab150676) was used to 
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stain RNA and DNA. Slides stained with hematoxylin/eosin were analyzed by using NIS-Element 
AR. For this analysis, the growth plate defects were defined as the areas between borders of intact 
growth plates flanking the injury sites (Figure 5-1). Percentages of fat and bone within the defect 
sites were calculated as 
Area of bone or fat
Area of defect
× 100%. Safranin O stained slides were used to analyze 
chondrogenesis. Percentage of the chondrogenic area was calculated as 
Area of the chondrogenic region
Area of hydrogel
× 100% . Tissue composition within the drill holes was also 
analyzed. The regions of interest were defined as 15 mm × 2 mm rectangles within the drill holes. 
The drill holes were identified by landmarks such as clear boundaries of bone and fat, and residual 
hydrogel within cortical bones. Quantity and thickness of the bony tether were measured using 








Figure 5-1 Area for growth plate defect analysis (yellow box).  
5.2.5  Statistical Analysis  
Statistical analysis was performed on histology measures using t-tests and one-way 




5.3.1  Growth Plate Defect Analysis 
15 mm deep growth plate defects were created laterally on proximal tibias by using a 4.5 
mm drill bit, mimicking the bony tether resection in pediatric patients. Two types of autologous 
BMSC-laden PGH hydrogels were used as the interpositional material in 13 legs, while the other 
three legs were left untreated. The groups were assigned randomly. One sample from the untreated 
group was lost during sectioning. Thus, 15 samples were analyzed.  
After three months, the growth plate appeared severely damaged at the injury site, 
regardless of the groups. A radiolucent smear (Figure 5-2) was seen under the injured growth 
plate in all legs. Focal widening (Figure 5-3) of the growth plate occurred, with an average height 
of 2.83 ± 0.10 mm compared to normal 0.63 ± 0.07 mm. Fragments of growth plate cartilage were 
found deep in the metaphysis, with fainter Safranin O stain compared to the intact growth plate 
(Figure 5-4 A). In some cases, the hypertrophic cells in the trapped cartilage did not calcify. The 
appearance of the damaged growth plate varied. Some lost the columnar cellular organization 
















Figure 5-4 Fragments of growth plate cartilage. Safranin O staining of the growth plate. A) Cartilage in the 




Trabecular bone, fat, growth plate fragments, and sometimes hydrogel fragments were 
found within the growth plate injury site. A small amount of fibrous tissue and blood vessels were 
also observed. The untreated defects contained higher bone content (53 ± 7.0%) compared to the 
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defects treated with tri-layered (18 ± 12%, p=0.0125) and homogeneous hydrogels (26 ± 12%, 
p=0.09). No significant difference was found between the two hydrogel groups. The tri-layered 
and homogenous hydrogel groups appeared to contain more fat compared to the untreated group 
(38 ± 25% and 35 ± 17% respectively versus 3.6 ± 3.62%).  
The growth plate is an undulating disc in growing children rather than a flat and smooth 
plate seen in newborns [31]. Therefore, it is difficult to make a defect following the growth plate 
anatomy perfectly using a straight drill bit. Although all 15 defects analyzed involved the growth 
plate, only two were drilled right at the growth plate (Figure 5-5 A). In four samples, the majority 
of the drill hole was located in the epiphysis (Figure 5-5 B). Six were in the metaphysis (Figure 
5-5Figure 5-5 C) and the other three intersecting the growth plate obliquely, with a part in the 
epiphysis and a part in the metaphysis (Figure 5-5 D). The epiphyseal drill holes had significantly 
more fat (68 ± 17%) compared to the ones made in the growth plate (39 ± 19%, p=0.0076) or the 





Figure 5-5 Schematic of hydrogel insertion. EP= epiphysis; MP= metaphysis. A) Right at the growth plate; 













5.3.2  Bony Tethers 
Bony tethers were seen in all legs, with widths ranging from 28 um to 1665 µm. A 100 
µm tether was found between the inserted hydrogel and the neighboring growth plate (Figure 







Figure 5-6 Bony tether between the hydrogel and the growth plate (indicated by the arrow). Hematoxylin 
and eosin staining of the growth plate.  
500 µm
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5.3.3  The Fate of the Hydrogels and Stem cells 
Histology revealed that the interpositional hydrogels had been resorbed in various 
degrees. The percent area occupied by hydrogel within the drill hole was significantly higher 
when in the metaphysis (27 ± 31 %) compared to in the epiphysis (0%, p=0.0001) and right at the 
growth plate (1.4 ± 3.8 %, p<0.0001). Small fragments (< 5 mm2) were often trapped in the 
cortical bone, regardless of the location of insertion (Figure 5-7). Hydrogels initially inserted in 
the epiphysis were barely seen after three months. A large quantity of fat was present within the 
defect site, with some in shape and size resembling the cross section of the inserted hydrogel 
(Figure 5-8 A). In some cases, small fragments of hydrogels also appeared in the metaphysis 
(Figure 5-8 B. In contrast, the hydrogels placed in the metaphysis were more likely to remain 
(Figure 5-9). In three out of eight cases, the hydrogel area was greater than 21 mm2, roughly 35% 
of the size at day 0. The hydrogels below the growth plate did not travel up as the bone grew. The 





Figure 5-7 Hydrogel fragments in cortical bone. Hematoxylin and eosin staining of the growth plate. A) 





Figure 5-8 Hematoxylin and eosin staining of the growth plate. A) Fat in the epiphysis (dashed line); B) 





Figure 5-9 Hematoxylin and eosin staining of the growth plate. The hydrogels placed in the metaphysis were 




The remnant hydrogels were surrounded by fibrous capsules (Figure 5-10 A, B). 
Multinucleated giant cells were seen within the capsules as well as on the periphery of the 
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hydrogels (Figure 5-10 B). These cells were crescent-shaped, with nuclei aggregated on one end 
of the cells, and appeared to have ruffle border (Figure 5-10 C). These cells also stained positive 







Figure 5-10 Hematoxylin and eosin staining of the growth plate(A-C). A) Hydrogel surrounded by a fibrous 
capsule; B) multinucleated giant cells within the capsules and on the periphery of the hydrogels; C) 
morphology of the multinucleated giant cells; D) RANK immunostain (green). 
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Chondrogenesis was observed in the three largest metaphyseal hydrogel implants 
(Figure 5-11). The most proteoglycan matrix was seen in a homogenous hydrogel (Figure 5-11 
A), having 4.6% Safranin O stained area. The other two hydrogels, one tri-layered (Figure 5-11 
B) and one homogenous (Figure 5-11 C), showed a few cells with faint Safranin O stain. 
Interestingly, the non-chondrogenic cells in these hydrogels can be categorized into two types: 
one had nucleus stained dark purple by hematoxylin, often found near proteoglycan producing 
chondrocytes; the other was not stained by hematoxylin, but Fast Green or eosin only. These 
“ghost cells” were seen in all remanent hydrogels, distributed throughout the scaffold, regardless 
of whether chondrogenesis occurred or not. DAPI stain showed that the “ghost cells” had nuclei, 
though the stain was much fainter compared to the hematoxylin positive cells (Figure 5-12 A). 
To further investigate the identity of the “ghost cells,” they were stained by Methyl Green 
Pyronin. The results showed that these cells had DNA, but RNA was undetectable (Figure 5-12 





Figure 5-11 Chondrogenesis in the hydrogels. Safranin O staining of the growth plate (GAG = red and pink). 





Figure 5-12 A) DAPI staining (blue). “Ghost cells” are indicated by white arrows; hematoxylin positive cells 
are indicated by yellow arrows. B) Methyl Green Pyronin staining. Methyl Green = bluish green (DNA); 
Pyronin Y = pink (RNA). Purple = presence of both DNA and RNA. “Ghost cells” are indicated by black 




No bone formation was observed within the hydrogels. The PGH hydrogels did not 
mineralize even when encapsulated in a bony environment (e.g., cortical bone), confirmed by CT 
images. Nevertheless, the hydrogel was susceptible to host tissue intrusion. Fibrous tissue and 






Figure 5-13 Bone penetrating hydrogel. Hematoxylin and eosin staining.  
5.4 Discussion 
This study demonstrated that goat could be used as a large animal model for studying 
growth plate injury. The PGH hydrogel was biodegradable and able to support stem cell 
chondrogenesis in situ. However, the use of a chondrogenic, mineralization resistant hydrogel 
alone as the interpositional material was not sufficient to prevent bony tether formation.  
A radiolucent cavity under the injured growth plate was seen three months post-
implantation. Similar cavities had been observed in children and minipig after fat implantation 
[186], as well as in sheep after allogenic growth plate chondrocyte implantation [27]. Such 
cavities had been shown to contain fat and elongate as the bone grew [186]. 
Widening of the growth plate was likely caused by damage to the metaphyseal blood 
vessels during the surgery. Increase in growth plate height after interrupting the metaphyseal 
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blood supply was reported by Trueta et al. and Nguyen et al. Insult to these blood vessels stopped 
alkaline phosphatase activity, arrested hypertrophic chondrocyte calcification and apoptosis, and 
eventually resulted in abnormally high cell numbers in the physeal column and persistent cartilage 
within the metaphysis [5, 187]. When the blood supply was restored, calcification resumed 
quickly [187].  
Similar to many previous attempts to repair the damaged growth plate through 
regenerative approaches, PGH hydrogels failed to prevent bony tether formation in this study. We 
found thin tethers, less than 100 μm in width, fitting tightly between the injured growth plate and 
the hydrogel. This observation suggested that the use of an interpositional material alone was 
unable to prevent cell infiltration between the epiphysis and metaphysis and the subsequent bony 
tether formation, regardless of how precisely it was implanted. Bony tether formation begins with 
infiltration of inflammatory cells into the injured site, followed by MSC-like progenitor cells. 
Then, the progenitor cells undergo chondrogenesis, osteogenesis, and angiogenesis. Ultimately, 
the cartilaginous tissue diminishes, and bone matrix matures [9]. In the present study, some tethers 
seemed stretched and elongated, probably due to tension generated by the growth of the 
surrounding healthy growth plate. The process of the architectural growth of bony tethers is 
unknown. Blood vessels were frequently observed within growth plate defects, as well as in the 
fibrous capsules surrounding the remanent hydrogel. Trueta et al. noted that the bony bridge 
formation always occurred following vascular invasion into the injured growth plate cartilage 
[187]. Chung et al. showed that systemic administration of an anti-VEGF antibody decreased 
bony tether formation in the damaged growth plate [188]. Therefore, using an interpositional 
material that releases anti-angiogenic or anti-osteogenic factors might be a more practical 
approach to prevent bony tethers. 
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Although unable to prevent tether formation, the PGH hydrogels appeared to decrease 
bone and increase fat within the growth plate injury sites compared to the untreated group. Most 
of the tethers seemed to have originated from the epiphysis, extending into the metaphysis. The 
epiphyseal hydrogel insertion site was often seen filled with adipose tissue. From these 
observations, it can be inferred that during the bony tether treatment procedure, accessing the 
tether and inserting the hydrogel from the epiphysis might favor fat formation rather than bone, 
refraining tether reformation. In the future, 3D analysis of tether size via CT is necessary to make 
a more precise comparison between the treated and the untreated groups. Also, it would be 
beneficial to determine the minimum size of a tether that would result in growth disturbance to 
design the success criteria for future interpostional materials. 
As expected, the PGH hydrogels were biodegradable in-situ. The degree of resorption 
appeared to be location-dependent rather than group-dependent. Hydrogels initially placed in the 
epiphysis were hardly seen after three months, whereas those in the metaphysis were more likely 
to remain. The metaphyseal hydrogels did not travel upwards with the growth plate as the bone 
grew; instead, they were buried deep into the metaphyseal bone. Maintaining proximity to the 
damaged growth plate is essential for local delivery of bioactive factors to prevent bony tether.  
This result further supported the inference that the interpositional hydrogel should be placed 
closer to the epiphysis rather than the metaphysis. Although 8% (w/v) hydrogels were mostly 
degraded after three months, 10% (w/v) hydrogel were seen to remain in the epiphysis in a 
previous study, suggesting the speed of gel degradation can be controlled by altering polymer 
concentration.  
The remanent hydrogels were found surrounded by fibrous capsules, suggesting the 
occurrence of foreign body reaction, a wound healing response after implantation of a biomaterial, 
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medical device, or prosthesis [189]. Multinucleated giant cells were observed within the fibrous 
capsules as well as on the periphery of the hydrogels, appearing to resorb the material. These cells 
seemed to be polarized, with nuclei aggregated on one side of the cell. Ruffle border was also 
seen under 60x magnification. This observation suggested that these cells were osteoclasts, which 
has morphology well described in the literature [190-192]. Enishi et al. and Kadoya et al. have 
reported osteoclast-like cells near implants in bone [193, 194]. To confirm the identity of these 
cells, staining for osteoclast markers is necessary. Tartrate-resistant acid phosphatase (TRAP) is 
one of the most commonly used markers for osteoclasts. However, in the present study, this 
marker was unsuitable due to the decalcification agent used. RANK is another osteoclast marker. 
Interaction between RANK and its receptor RANKL plays a vital role in osteoclast development 
[195, 196]. Immunostain showed that these crescent-shaped cells were indeed RANK positive.  
Nevertheless, RANK alone cannot confirm the identity of the cells. A panel of markers for 
osteoclasts is needed, such as vitronectin receptor, calcitonin receptor, cathepsin K protein, 
carbonic anhydrase II, vacuolar H+-ATPase, and integrin β3 [197-199].  
Sparse Safranin O stain in the hydrogel was observed in three samples, indicating the PGH 
was able to support BMSC chondrogenesis in-situ. No bone was formed within the hydrogel, 
confirmed by the CT results (not shown), consistent with our previous finding that the PGH 
hydrogel supported chondrogenesis and inhibited osteogenesis. However, to use PGH hydrogel 
as an interpostional material to regenerate physeal cartilage, further modification is needed to 
enhance chondrogenesis, for example, by incorporating a drug delivery system.  
The implanted stem cells and the host cells were distinguished by morphology and cell 
distribution, with the host cells having a fibroblast-like appearance and being more concentrated 
at the periphery of the hydrogel implant. Besides chondrocytes, two other types of cells were seen 
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within the hydrogel. One was often found adjacent to committed chondrocytes, round, with nuclei 
visible under hematoxylin, DAPI, and methyl green stains, and positive for Pyronin Y, an RNA 
stain. We speculate that these cells were at a very early stage of chondrogenesis, as a spectrum of 
chondrocyte-like cells were seen, from small round cells with faint GAG on the periphery, to 
large chondrocyte clusters rich in matrix molecules.  
The other was the majority of the cells, also round, unstained with hematoxylin or Pyronin 
Y, but DAPI and methyl green positive (DNA stains). They were uniformly distributed within the 
implanted hydrogel, suggesting the cells we encapsulated stayed alive throughout the experiment. 
Interestingly, the hematoxylin positive cells stained more strongly with DAPI than the 
hematoxylin negative cells, suggesting the chromatins might be packed differently between the 
two cell types, resulting in different dye-binding affinities. The hematoxylin-mordant complex is 
positively charged and binds strongly to both DNA and RNA [200, 201]. The lack of hematoxylin 
and Pyronin Y stains indicated that these cells contained an extremely low level of RNA, a 
characteristic of quiescent stem cells [202, 203]. To further investigate the identity of these cells, 
staining for stem cell markers are needed, as well as techniques to detect quiescent cells, which 
lack proliferation makers, such as Ki-67 and PCNA, and retain cell labels, such as 5’ bromo-2’-
deoxyuridine (BrdU) and tritiated thymidine. Being in the quiescent state is believed to prolong 
the survival of stem cells under metabolic stress and maintain their long-term genomic integrity 
[202, 204]. Therefore, a hydrogel inducing quiescence might enable lasting preservation of stem 
cells at the target site for regeneration. 
It is worth noting that the present study was primarily based on histological analysis, 
which revealed limited information due to its 2-dimensional nature and the plane of sectioning. 
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Bone volume quantification of using computed tomography will be performed in the future to 
further access the bony tethers and efficacy of the implanted hydrogels.  
5.5 Conclusion 
We have successfully created a goat model to study growth plate injuries. The PGH 
hydrogels were biodegradable and supported stem cell chondrogenesis in situ without showing 
mineral deposition. Although unable to prevent bony tether formation, implantation of the PGH 
hydrogels reduced bone and increased fat content within the damaged growth plate. Incorporating 
anti-angiogenic or anti-osteogenic factors into the interpositional hydrogel, and inserting the 
hydrogel from the epiphyseal end might be keys to prevent bony tether formation.  
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6.0 Overall conclusion and future work 
6.1 Conclusion 
Recapitulating the zonal architecture is deemed the key to regenerate functional growth 
plate cartilage [12]. The five success criteria of growth plate cartilage regeneration are 1) support 
cartilage formation; 2) prevent bony tether; 3) restore the zonal cell organization; 4) reestablish 
the appropriate signaling; 5) restore normal growth. This dissertation has focused on developing 
an interpositional device that meets the first two criteria. Based on the findings of the present 
study, the device will be optimized in the future, aiming to meet all five criteria.  
We have presented the development and evaluation of a stem cell-laden PEGDA-(GEL-
MA)-(HEP-MA) (PGH) hydrogel for growth plate injury repair. The PGH hydrogel was 
fabricated in-house and characterized for physiochemical properties including mechanical 
stiffness, swelling properties, and cytocompatibility. To evaluate the potential of the hydrogel to 
recreate the growth plate structure, its effects on chondrocyte phenotype progression were 
analyzed in vivo and compared to a conventional methacrylated gelatin hydrogel (GEL-MA only, 
often used in bioprinting applications and cartilage engineering). To evaluate its ability to drive 
differentiation of stem cells to growth plate chondrocytes, its effects on stem cell chondrogenic 
and osteogenic differentiation were evaluated both in vitro and in vivo. Finally, the efficacy of the 
stem cell-laden PGH hydrogel in regenerating cartilage and preventing bony tethers was accessed 
in a growth plate defect model in goats.  
The results showed that the PGH hydrogel was cytocompatible and able to maintain 
chondrocyte phenotypes. Compared to the GEL-MA only hydrogel, the PGH hydrogel 
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maintained glycosaminoglycan production by hypertrophic chondrocytes, arrested terminal 
differentiation, and successfully inhibited mineralization. While supporting chondrogenesis, it did 
not permit osteogenesis or mineral deposition by stem cells. When implanted into a growth plate 
defect, the PGH hydrogel was biodegradable and supported stem cell chondrogenesis. Although 
unable to completely prevent bony tether formation, implantation of the PGH hydrogel reduced 
bone and increased fat content at the defect site. To better evaluate the efficacy of the PGH 
hydrogel, the critical tether size needs to be determined.  
Overall, the PGH hydrogel has shown some degree of success in supporting cartilage 
formation and preventing bony tether formation. However, it failed to restore the zonal cell 
organization and normal growth. The reasons for the failure can be concluded as the following: 
1) The growth plate is a dynamic tissue. By the time BMSCs differentiate into chondrocytes, the 
growth plate has already traveled away from the implanted hydrogel; 2) The current PGH 
hydrogel degraded too fast when placed in the epiphysis; 3) Even when the hydrogel was placed 
properly into the growth plate defect, tethers were able to form around it.  
From this study, we have learned that using an interpositional material that releases anti-
angiogenic or anti-osteogenic factors might be a more practical approach to prevent bony tethers. 
Also, during the bony tether treatment procedure, accessing the tether and inserting the hydrogel 
from the epiphysis might favor fat formation rather than bone, hampering tether reformation. The 
composition of the hydrogel needs to be optimized for slower degradation.  
This work demonstrated that the PGH hydrogel has the potential to regenerate growth 
plate cartilage while preventing bony tether formation. It may also be suitable to regenerate other 
stratified cartilaginous interfacial tissues that contain zones of different cellular phenotypes, such 
as the temporal mandibular condyle.  
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6.2 Future Work 
The mechanisms of the PGH hydrogel’s effects on chondrocyte phenotypes and stem cells 
chondrogenesis and mineralization may be better defined through continued investigations. 
We hypothesize that heparin plays a significant role in driving the material effects by 
binding to consensus sequences, modulating and prolonging signaling of endogenous growth 
factors that promote GAG production and inhibit terminal differentiation [74, 132, 133]. For 
example, heparin prolongs TGFβ activity by protecting them from enzymatic degradation [46, 
133]. As a result, more TGFβ-2 might be available to upregulate PTHrp expression, thereby 
enhancing its downstream activities, such as chondrocyte proliferation, matrix production, and 
hypertrophy prevention [128-131]. Heparin also promotes FGF signaling by facilitating its 
interaction with the FGFR (FGF receptor) [134, 135]. FGF has been reported to obstruct 
chondrocyte hypertrophy and terminal differentiation [2, 126, 127]. In addition, heparin 
strengthens the interaction of hedgehog (Hh) with interference hedgehog, a component of the Hh 
signaling pathway parallel or upstream of Patched (Ptc) [132, 136].  IHH has been shown to delay 
chondrocyte hypertrophy by stimulating the production of PTHrp [2]. Heparin may also interfere 
with the Wnt signaling pathways, which are critical in chondrocyte differentiation. Heparin binds 
to metalloproteinases MMP-13, ADAMTS-4, ADAMTS-5 as well as a tissue inhibitor of 
metalloproteinases, TIMP3. Such binding prevents the interaction of these factors with LRP1 
[205], an endocytic receptor that facilitates coendocytoses of MMP-13, ADAMTS-5, and TIMP-
3  [206]. LRP1 has also been shown to inhibit the canonical Wnt signaling pathway by disrupting 
the formation of the Wnt receptor HFz1-LRP6 complex [207] and the subsequent chondrocyte 
terminal differentiation [208, 209]. Binding of heparin with LRP1 ligands might increase the 
availability of LRP1 to block the canonical Wnt signaling, leading to inhibition of hypertrophy. 
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The non-canonical Wnt signaling pathway is speculated to be unaffected by LRP1 because it does 
not involve LRP6 [167, 210]. The hypothesized signaling mechanisms discussed above are 
summarized in Figure 6-5. It would also be interesting to study mineralization in the PGH 
hydrogels without cells, matrix vesicle secretion by chondrocytes, the composition and crystal 
structure of mineral deposited, and the effect of substrate stiffness on the cytoskeletal structure 
and focal adhesion complex. 
Future work may also be conducted to improve the current PGH hydrogel by a) 
incorporating anti-angiogenic or anti-osteogenic factors to prevent bony tether formation entirely, 
and b) incorporating a drug delivery system to enhance stem cell chondrogenesis. Furthermore, it 
may be beneficial to characterize and optimize physiochemical properties of the PGH hydrogel 
so that it can be of potential use in other applications, such as monolithic casting, injectable, and 
bioprinting.  
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Figure 6-1 Subcutaneous growth for 8 weeks, Safranin O and Fast Green. PGH augmented GAG secretion 





Figure 6-2 Methyl Green Pyronin Y Staining revealed that compared to GEL (1-3, 7-9, 13-15), PGH (4-6, 10-
12, 16-18) maintained RNA level (indicating protein synthesis) in hypertrophic chondrocytes over 8 weeks of 





Figure 6-3 Col2 and Col10 deposition by the different chondrocyte populations over 1, 3, and 8 weeks of 
growth in vivo in GEL and PGH hydrogel constructs. Immunostain red = Col2, green = Col10,  blue = 





Figure 6-4 Col1 and Col10 deposition by the different chondrocyte populations over 1, 3, and 8 weeks of 
growth in vivo in GEL and PGH hydrogel constructs. Immunostain red = Col1, green = Col10,  blue = 





Figure 6-5 Hypothesized signaling pathway underlying the effects of PGH on chondrocyte GAG production 
and terminal differentiation. 
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Appendix B Investigation of the Potential Mechanisms that Drive Hydrogel Effects 
B.1 Effects of metalloproteinases inhibitor on chondrocyte phenotype 
To determine the mechanism that drives hydrogel effects, we further investigated 
differentiation state progression using in vitro cultures where we added inhibitors of matrix 
metalloproteinases (MMP, inhibitor =GM6001 ) to the constructs with chick chondrocytes (n=3). 
Samples were collected after one week for histological and PCR analysis.  
We hypothesized that the greater collagen content in GEL-MA compared to PGH 
hydrogels caused the faster progression to hypertrophy and mineralization in GEL-MA, because 
endogenous MMP activity would produce collagen fragments that promote hypertrophy [211] 
However, the MMP inhibition did not significantly alter COL10 secretion in GEL-MA in vitro, 
but it did increase GAG and COL2 matrix secretion. This is likely not due to increased retention 
of these secreted molecules because PCR results also show up-regulation of GAG and COL2 gene 
expression. We propose that the PGH hydrogel composition promotes retention and activation of 





Figure 6-6 In vitro cultures of hypertrophic chondrocytes at 1 week. S.O & Fast Green. Control= untreated 





Figure 6-7 In vitro cultures of hypertrophic chondrocytes at 1 week. Green=COL10; Red=COL2; 






Figure 6-8 Gene expression analysis of untreated (Control) and GM6001 supplemented (Treated) hydrogel 
cultures at 1 week (normalized to GAPDH). COL2=collagen type 2α1, COL10=collagen type 10, 
AGN=aggrecan, ALPL= tissue non-specific alkaline phosphatase. 
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Appendix C Effects of PGH Alone on Mineral Deposition 
Cell-free GEL and PGH were cast in transwells (12 well dish, 1cm2 culture area, 3µm 
pore size). 10x PBS (pH 7.4, 67 mM PO4) was added to one side of the well, and 100 mM CaCl2 
solution was added to the other (n=3, bottom well=2 mL, top well = 500 µL solution). 
Photographs were taken at 0, 0.5, 1, and 3 hours to monitor mineral deposition. Compared to GEL 













Figure 6-10 Photographs of the hydrogels at 0 (A), 0.5 (B), 1 (C), and 3 hours (D). Both PGH and GEL 
hydrogels appeared to be more opaque after 3 hours. C/P= CaCl2 in the top insert and PBS in the bottom 







Figure 6-11 Photographs of the hydrogels at 3 hours. A and D are no hydrogel controls. B and E are GEL 
hydrogels. C and F are PGH hydrogels. C/P= CaCl2 in the top insert and PBS in the bottom well. P/C = PBS 





Figure 6-12 Photographs of the hydrogels at 3 hours. A - D are PGH hydrogels. E and F are GEL hydrogels. 
GEL C/P hydrogels adhered tightly to transwell membranes and could not be removed without damaging 
the hydrogels. C/P= CaCl2 in the top insert and PBS in the bottom well. P/C = PBS in the top insert and 
CaCl2 in the bottom well. 
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